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Breast cancer is a heterogeneous disease state with several challenging frontiers. 
In particular, aberrations in the Phosphoinositide-3-kinase (PI3K) and Mitogen Activated 
Protein Kinase (MAPK) pathways have been linked to increased breast cancer 
proliferation and survival. It has been proposed that these survival characteristics are 
enhanced through compensatory signaling and crosstalk mechanisms. The crosstalk 
between PI3K/Akt and MEK1/2/ERK1/2 has been characterized in several systems. 
However, new evidence suggests that MEK5/ERK5, a member of the MAPK family, is a 
crucial component in the proliferation and survival of several aggressive cancers. We 
hypothesize that inhibiting both PI3K/Akt and MEK5/ERK5 pathways will decrease cell 
viability while maintaining limited collateral toxicity. In this study, we examined the 
effects of dual inhibition of PI3K/Akt and MEK5/ERK5 in a panel of hormonally diverse 
 v 
cell lines. Additionally, we investigated dual inhibition in triple-negative breast cancer 
(TNBC) and tamoxifen resistant models. Both of which do not currently have targeted 
therapy available. Our results (in TNBC cells) indicate that the dual inhibition strategy 
was more effective than single inhibition due to the loss of crosstalk between the two 
pathways. In particular, a loss of Bad phosphorylation at two distinct sites was observed 
with dual inhibition. Interestingly, this signaling pattern was observed without disturbing 
the ERK1/2 pathway. Furthermore, the inhibition of both pathways led to p21 restoration, 
decreased cell proliferation, and induced apoptosis. Also, the dual inhibition strategy was 
determined to be synergistic in TNBCs and was nontoxic in the non-neoplastic MCF-10A 
cell line. In summary, the results from this study provide a unique perspective into the 
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1.1.1 Cancer Epidemiology and Etiology 
 
Cancer is the second leading cause of death in the United States with an estimated 1.7 
million new cases and 600,000 deaths annually. Of the various cancer types, breast and prostate 
cancer are the most common for women and men, respectively (Figure 1-1A). Recent advances 
in early detection and treatment have led to approximately 2.6 million adverted cancer deaths 
since 1990 (Siegel et al. 2019). However, many challenges remain in treating cancer because 
cancer is a diverse disease of 200 distinct types and is considered to be a “moving target” due to 
the vast genetic and epigenetic alterations (Komarova, 2015). 
According to the American Cancer Society, 250,000 new cases of breast cancer will 
develop each year resulting in 40,000 deaths (American Cancer Society, Breast cancer Facts and 
Figures 2017-2018). Breast cancer remains the second leading cause of cancer related deaths in 
women and 1 in 8 women will develop the disease in their life-time. Almost all new cases (95%) 
occur in women over 40 years of age (DeSantis, 2017). Breast cancer deaths have decreased 
steadily since 1990 due to improvements in detection, treatment, surgery and molecular profiling 
(Figure 1-1 B). Exposure to ionizing radiation and estrogens are risk factors for developing 
breast cancer. In addition to external factors, breast cancer arises from a series of genetic and 
epigenetic events that result the inhibition of apoptosis, increased invasiveness, immune 






Figure 1-1. Cancer incidence by gender and female death rates by site. Male (left) and 
Female (right) incidences by site since 1975 (A). Female deaths by site since 1930 (B). Adapted 
from Siegel et al. ,2019. Reproduced with permission; License number: 4565101399877. 
 
1.1.2 Breast Cancer Anatomy and Pathophysiology 
 
The female breast contains two main anatomical features: lobules and ducts. Breast ducts 
connect the lobules via a converging nipple-areola complex (Figure 1-2A). The ducts are 
comprised of three types of cells: luminal, basoluminal, and basal (Figure 1-2B). The basal cells 
are responsible for contraction of the ducts while the luminal cells line the ducts. Duct cells are 
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epithelial in origin and cancers that arise from the ducts are called Ductal Carcinoma In Situ 
(DCIS) and Invasive Ductal Carcinoma (IDC). DCIS means that the cancer is localized in the 
duct and has not disseminated to lymph nodes or formed distant metastases. The incidence of 
both DCIS and IDC increases after the age of 50 due to fluctuations in estrogen concentration 
and accumulation of somatic mutations (Figure 1-3). DCIS represents 83% of in situ cases while 
IDC represents 80% of invasive cases. Malignancies can also form in the lobules to become 
Lobular Carcinoma In Situ (LCIS) and Invasive Lobular Carcinoma (ILC); albeit at lower rates 
than their respective ductal counterparts (Collins et al. 2005; Sanders et al. 2005; Erbas et al. 
2006). 
 
Figure 1-2. Anatomical and cellular structure of the female breast. Anatomy of the female 





Figure 1-3. Breast cancer In Situ and invasive cases increases over 50 years old.  
Rates of In Situ and Invasive breast cancer per 100,000 US females since 1975. Adapted from 
De Santis et al. 2017. Reproduced with permission; License number: 4565100729408. 
 
Breast cancer is staged according to the size and characteristics of the primary tumor (T), 
involvement of regional lymph nodes (N), and presence of metastatic lesions (M). TNM stage 
ranges from 0 to IV (Edge et al. 2010). DCIS is commonly referred to as TNM stage 0 and 
considered to be “in place” or pre-invasive. Whereas, metastatic IDC are considered to be TNM 
stage IV. Intermediate stages are determined by tumor size and degree of lymphatic involvement 
(Shahar 2005). Sentinel lymph node biopsy in the axillary region is a commonly performed 
procedure used to determine lymphatic involvement in invasive breast cancer (Strom 2005). In 
general, low grade and low TNM score (Stage 0-1) tumors are characterized as “local” and 
therefore DCIS. The treatment regimen for DCIS is radiation followed by surgery and 
postoperative radiation. Surgical technique has drastically improved since early breast surgeries 
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in the 1950s. Instead of radical mastectomies, patients today have tumors removed and 
immediately undergo reconstructive surgery after the pathology is determined to be clear (Cotlar 
et al. 2003). Due to advances in surgery, the prognosis for localized DCIS is favorable with over 
93% 5-year survival rates across all ethnicities of US women (Figure 1-4A). Mid-grade and mid 
TNM score (Stage II-IIIa) are more difficult to characterize as DCIS or IDC. However, their 
prognosis is relatively favorable with approximately 80% 5-year survival across all ethnicities 
(Figure 1-4A). Lastly, patients with “distant” pathology are considered high grade and high 
TNM score (Stage IV) have a worse prognosis than localized or regional disease with 5-year 
survival rates raining from 26-39% (Figure 1-4A).  
In addition to tumor staging, biopsies are examined by pathologists to determine the 
morphological appearance, molecular, and genetic characteristics of the tumor. Tumor grade 
refers to several factors such as the rate of growth, the degree of differentiation, mitosis, and 
metastatic spread. Tumors with poor differentiation, multiple mitoses, and high Ki67 staining (a 
proliferative marker) are said to be high grade. Similar to Stage IV tumors, high-grade tumors 
have a worse prognosis (Centers for Disease Control and Prevention, 2017). In breast cancer, 








Figure 1-4. Breast cancer 5-year survival based on site at detection and race. 
Patients were diagnosed from 2007 to 2013 and were followed through 2014 (A). NHW= non-
hispanic white, NHB= non-hispanic black, API= Asian/Pacific islander, and AI/AN= American 
Indian/Alaska Native. Adapted from National Center for Health Statistics, Centers for Disease 
Control and Prevention, 2017. Reproduced with permission; License number: 4565100729408. 
 
The metastatic process is a primary driver of IDC mortality and presents a significant 
challenge for treatment (Figure 1-4A). Metastasis begins with changes in the primary tumor 
microenvironment. First, tumor cells secrete vascular endothelial growth factor (VEGF) in 
response to the hypoxia of the tumor microenvironment. VEGF expression is increased under 
hypoxia due to the stabilization of hypoxia inducible factor 1 alpha (HIF1a) (Galanis et al. 2008). 
Neovascularization (angiogenesis) occurs in response to the expression of VEGF. However, the 
newly formed vessels are leaky and offer less of a barrier to cell invasion than compared to 
normal vasculature. Local invasion begins with the cell transformation process called epithelial 
to mesenchymal transition (EMT). EMT is characterized by a loss of cell-cell interactions and 
cytoskeletal rearrangements. E-cadherin and claudins are key proteins that establish cell-cell 
interactions (Hugo et al. 2007). Loss of E-cadherin promotes cell-matrix interactions rather than 
cell-cell interactions. Unlike normal cells, cancer cells do not under go apoptosis (programmed 
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cell death) when they detach from neighboring cells. Therefore, cancer cells are not bound to 
their tissue of origin and can migrate to more nutrient rich microenvironments.  
Regulation of E-cadherin is both reversible and irreversible. Irreversible mechanisms 
such a mutations primarily occur in lobular carcinoma and are rare in IDC (Cowin et al. 2005). 
Epigenetic suppression of E-cadherin through promoter methylation is common in IDC and is 
often driven in response to a change in metabolic demands (Graff et al., 2000). In mesenchymal 
cells, loss of E-cadherin frequently accompanies the expression of N-cadherin (Cowin et al. 
2005). Clinically, loss of E-cadherin is breast cancer is correlated with increased invasiveness 
and a worse prognosis (Paredes et al., 2007). Down regulation of E-cadherin promotes Wnt 
signaling by releasing beta catenin from the membrane (Nelson & Nusse, 2004). Once activated, 
beta catenin promotes an invasive phenotype by activating EMT related genes: TGFbeta, and 
snail (Guarino et al., 2007, Katoh and Katoh, 2008). Additionally, activation of survival 
pathways such as, PI3K, MAPK, and Smad also promote EMT (Peinado et al., 2003). Another 
feature of EMT transformed cells is that they secrete matrix metalloproteinases (MMPs). MMPs 
are enzymes that cleave fibrin, plasminogen, and type IV collagen (Weber 2007). Therefore, 
MPP secreting EMT transformed cells have increased motility. Additionally, the mechanical 
pressure that arises from excessive proliferation in the primary tumor also contributes to 
basement membrane penetration. Once cells have escaped the primary site, with the help of 
MMPs, they must survive in the vascular system until they reach a metastatic site. Detached 
cancer cells are anoikis resistant, meaning they are anchorage independent. Although cancer cells 
have numerous survival advantages, metastasis is an inefficient process and only 1 in 10,000 
cells (0.1%) survive the journey through circulation (Anders and Carey, 2009). The cells that 
arrive at the metastatic site (lung, bone, and liver are most common) undergo another 
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transformative change from mesenchymal to epithelial and begin to grow and secrete growth 
factors and hormones that act to attract cells in blood stream to the metastatic site (Figure 1-5). 
Once a metastatic colony is established, the affected is a risk for tissue destruction and 
dysfunction. In particular, metastatic colonies in the lungs, brain, or bone are devastating due to 





Figure 1-5. Metastatic process in breast cancer. Anatomical representation of metastisis (A). 
Invasion and Metastatic process (B). http://clinchem.aaccjnls.org/content/60/1/197 Reproduced 
with permission; License number: 11807713. 
 
1.1.3 Molecular profile of Invasive Ductal Carcinoma and current treatments 
 
 Under normal conditions, hormones such as estrogen and progesterone maintain the 
female breast. In cancer cells, these hormones are mitogenic and stimulate excessive growth. As 
mentioned earlier, the ducts of the breast have three main types of cells: basal, basoluminal, and 
luminal. In general, the hormone receptor positive breast cancers resemble the luminal cells of 
the ducts. Luminal cells tend to express estrogen receptors (ER) on their cell surface and make 
up the majority of IDCs (Figure 1-6). Luminal cells are further subdivided into luminal A and B 
(Perou et al., 2000, Sorlie et al., 2001). Luminal A cells express ER and the progesterone 
receptor (PR). Luminal B cells also express ER and PR. However, Luminal B cells also express 
human epidermal growth factor receptor 2 (HER2). Since Luminal B cell express three hormone 
receptors they are considered to be “triple-positive.” Conversely, triple-negative breast cancer 
cells (TNBCs) lack the ER, PR, and HER2 receptors. TNBC cells resemble the basal cells of the 
ducts. Heterogeneity is also observed in basal like TNBCs with the cells divided into Basal A 
and Basal B.  A study found that 123 out of 172 TNBC samples (71%) were Basal A (Bertucci et 
al. 2008). Basal A cells have epithelial character and express Keratin 5 and 14. Whereas, Basal B 
cells exhibit mesenchymal character and express vimentin (Neve et al., 2006). 
Endocrine therapy is the primary treatment for ER+ and HER2+ (luminal A and B) breast 
cancer. Prognosis for luminal IDC is favorable compared to the other subtypes. However, 
resistance to endocrine therapy is a major mechanism of relapse and mortality (Creighton et al., 
2009). Basal cell type is referred to as triple-negative breast cancer (TNBC). These cancers have 
the least favorable prognosis and do not respond to endocrine therapeutic intervention since they 
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lack all three hormone receptors: ER, PR, and HER2. As such, TNBCs have a worse prognosis 
compared to hormone positive IDC and chemotherapy is the primary treatment option (Figure 1-
6).   
 
Figure 1-6. Molecular subtypes of invasive breast cancer and incidence by race. 
Molecular spectrum of IDC with histological and clinical correlates (A). Data represented as new 
cases per 100,000 of US population in 2017. Cases further divided by race and hormonal profile 
(B). NHW= non-hispanic white, NHB= non-hispanic black, API= Asian/Pacific islander, and 
AI/AN= American Indian/Alaska Native. Adapted from National Center for Health Statistics, 
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Figure 1-7. Treatment paradigm for Metastatic Breast Cancer. 
Adapted from MD Anderson Manual of Medical Oncology, Third edition (2016).  
 
Agent Response rate Response duration 
 
Citation(s) 
Doxorubicin 25-60% 7.8 months Oosterom et al., 
1986 
Paclitaxel 21-62% 7.5 months Sledge et al., 2003 
Docetaxel 37-57% 8.4 months Harvey et al., 2006 
Capecitabine 30% 8.1 months Blum et al., 1999 
Ixabepilone 11.5% 5.7 months Perez et al., 2007 
Eribulin 29% 5.8 months McIntyre et al., 2014 
Docetaxel/Capecitabine 42% 6.1 months O’Shaughnessy et 
al., 2002 
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Figure 1-8. Gompertzian kinetics of tumor growth and treatment. Adapted from Katzung 
and Trevor 2015. 
 
Systemic chemotherapy is the current standard of care for metastatic breast cancer 
(MBC). Single-agent chemotherapy is administered IV every three weeks with one off week. 
The dose depends on the agent however dose-dense therapeutic regiments as described above are 
more effective than two weeks on and one week off. This is because infrequent scheduling of 
treatment courses allows the tumor to grow faster than the kill rate (dark blue line), whereas 
more intensive and frequent treatment (teal line) is more effective. Similarly, frequent and 
intense dosing given after surgery is also effective (green line) (Figure 1-8). Concurrent therapy 
is more effective than single therapy although toxicities are more common. (Norton 2005). 
Doxorubicin was one of the first agents used to treat MBC. Doxorubicin is anthracycline-
based chemotherapy that disrupts replication of DNA. More specifically, the planer structure of 
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Doxorubicin allows it to intercalate between two base pairs of DNA and stabilize the 
topoisomerase II complex, thus halting replication. Doxorubicin is administered IV every three 
weeks with one off week. Phase II and III trial data reported a 25-60% response rate for patients 
with MBC. Note that “response” refers to partial or complete response. Additionally, the 
duration of the response was 7.8 months (Van Oosterom 1986; Table 1-1). Taxanes are another 
class of agents used for MBC. Taxane-based therapies function by inhibiting the formation of the 
mitotic spindle. More specifically, Paclitaxel targets tubulin and stabilizes it polymerization, 
which inhibits mitotic spindle formation. Thus, Paclitaxel causes G2/M cell cycle arrest and 
induces apoptosis. Paclitaxel is administered via IV every three weeks with one week off. 
Clinical trial data report a 21-62% response rate for patients with MBC. The duration of response 
was 7.5 months (Sledge et al., 2003; Table 1-1). Ixabepilone is a microtubule stabilizer that used 
in taxane-resistant tumor cells. However, the efficacy is limited with only 11.5% of patients 
responding in trials (Perez et al., 2007; Table1-1). Capecitabine is an antimetabolite therapy that 
is converted to 5-FU in vivo. Once converted, 5-FU inhibits thymidylate synthase and ultimately 
DNA synthesis. In a Phase II trial, 30% of MBC patients responded to Capecitabine, and the 
response duration was 8.1 months (Blum et al., 1999; Table 1-1). Lastly, combinations of 
Docetaxel/Capecitabine have been tried in MBC but had similar response rates to monotherapy 
(42%) (O’Shaughnessy et al., 2002; Table 1-1). 
The lack of sustained response and high collateral toxicity associated with chemotherapy 
have underscored the need for targeted therapy for MBC. New advances in genomic screening, 
such as next generation sequencing (NGS), have revealed promising leads for targeted therapy. 
More specifically, driver mutations in the MAPK and PI3K/Akt survival pathways have become 
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a central focus for developing targeted agents (Bailey et al. 2018). Successful translation of these 
agents to the clinic and implementation as the standard of care is the goal of precision oncology.  
 
1.1.4 Genetics and Driver Mutations in Breast Cancer 
 
Genetic alterations in breast cancer are familial associated 20-25% of the time but the 
vast majority of events are somatic or sporadic mutations in tumor suppressor genes or oncogene 
activation (Buchholz 1999). The BRCA1 and BRCA2 genes are strongly associated with familial 
inheritance (germ line) and patients with this mutation tend to develop ER+ cancer and are at an 
increased risk for ovarian cancer (Petrucelli 2010). BRCA mutations occur through point 
mutations and complex rearrangements less frequently occur (<1%). BRCA mutations affect the 
ability of a cell to repair double strand breaks. As a result, additional mutations, amplifications, 
and gene fusions result in tumor formation. BRCA mutant breast and ovarian cancer patients are 
responsive to PARP inhibition due to synthetic lethality (Farmer et al., 2005). Synthetic lethality 
occurs when two simultaneous gene ablations results in a loss of viability. In the case of BRCA 
and PARP, the loss of both double strand break repair mechanism results in catastrophic DNA 
damage and eventually apoptosis (Farmer et al., 2005). Preemptive removal (mastectomy) is 
sometimes indicated for patients harboring BRCA mutations (Hartman 1999, Rebbeck 2004).  In 
addition to familial inheritance, genetic screening for mutations of tumor suppressors: PTEN 
(proliferation), TP53 (cell cycle), and CDH1 (E-cadherin expression) are also an effective 
strategy to assess risk. Since, the loss of function of PTEN, TP53, or CDH1 increases the risk of 
cancer formation due to unregulated growth and proliferation.  
Although hormone therapy and surgery are the mainstays in breast cancer therapy for 
localized disease there are few options for invasive cases. Therefore, attention has shifted to the 
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genomic profile of many cancers, including invasive breast cancer, in hope of discovering 
“actionable” driver mutations that can be exploited for therapeutic benefit.  
Bailey et al., 2018 analyzed the genomics of 9423 tumors that represented 33 different 
tumor types (including breast). 299 driver genes and 579 consensus mutations (out of 3437 
mutations) were identified. The most common driver mutations were TP53 (27 out of 33 tumor 
types) followed by PIK3CA, KRAS, and PTEN (15 or more cancer types). The main 
mechanisms of mutation were truncation and missense for TP53 and missense for KRAS and 
PI3KCA. Interestingly, oncogenic driver mutations in the survival pathways MAPK and PI3K 
were found in 24 and 22 distinct cancer types, respectively. Discovery of the V600E BRAF 
mutation in melanoma has directly led to the development of FDA approved inhibitors 
Dabrafenib (BRAFi) and Trametinib (MEKi). This is one of the earliest examples of mutation 
driven precision oncology (Figure 1-8). Thyroid cancer is another example of using mutations to 
drive clinical innovation. Receptor tyrosine kinase inhibitors such as, Vandetanib, Cabozantinib, 
and Sorafenib are standards of care for medullary, papillary, and follicular thyroid cancers. 
Additionally, BRAF mutant anaplastic thyroid cancer is targeted with Dabrafenib (BRAFi) and 
Trametinib (MEKi). Gastrointestinal stromal tumor (GIST) is another example of successful 
targeted therapy. GIST patients with the BCR-Abl gene fusion are treated with Imatinib, a drug 
originally used for chronic myeloid leukemia (CML). As more of the genome is uncovered for 
each cancer, the number of successful FDA approvals is likely to increase. However, some 
cancers such as breast cancer are lagging despite the large number of “actionable” mutations 
across the disease. Therefore, in our study we will examine the genetic prolife of cell lines used 
but recognize that these mutations may not be “oncogenic addictions” that are susceptible to 




Figure 1-9. Summary of mutation driven precision oncology by cancer type.  
From the figure above, shows the tumors types that have had successful therapies developed 
from actionable mutations. For SKCM, melanoma, in particular V600E BRAF mutant melanoma 
have used Dabrafenib (BRAFi) and Trametinib (MEKi) to successfully treat patients with 
precision oncology. Adapted from Bailey et al. 2018. 
 
1.1.5 MAPK and MEK5/ERK5 pathways  
 
The mitogen-activated protein kinase (MAPK) pathway is a family of kinases that 
transduce extracellular signals intracellularly and influence cellular processes such as 
proliferation, differentiation, motility, metabolism, development, survival, and gene expression. 
There are six members of the MAPK family in mammals, 4 are extracellular signal related 
kinases (ERK) ERK1/2, ERK3/4, ERK5, and ERK7/8. The other two members are c-Jun N-
terminal kinase (JNK1/2/3) and p38 (a/b/c/d) (Krishna and Narang 2008). Each MAPK contains 
a three tiered kinase signaling cascade that are initiated by a multitude of extracellular signals 
such as, growth factors, cytokines, and stress. At the receptor level, MAPKs are activated by 
Receptor Tyrosine Kinases (RTK), G-protein coupled receptors (GPCR), and hormone receptors 
(Flaherty et al., 2010). Upon activation, the receptor undergoes a conformational change that 
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facilitates the activation of the first tier of the MAPK pathway: Mitogen-activated protein kinase 
kinase kinase (MAPKKK). MAPKKK then phosphorylates Mitogen-activated protein kinas 
kinase (MAPKK), which subsequently phosphorylates Mitogen-activated protein kinase 
(MAPK). MAPK then phosphorylates cytosolic and nuclear substrates. The specific substrates 
that are modified depend on the initial signal, the MAPK activated, and how long the signal in 
maintained (Marshall 1994). 
The Ras/Raf/MEK1/2/ERK1/2 pathway plays a key role in various cellular processes 
such as proliferation, survival, motility, and development. In particular, ERK1/2 is ubiquitously 
expressed in all tissue types and is key for embryonic angiogenesis and proliferation. Knockout 
of the ERK2 gene in mice is embryonically lethal, thus underscoring its importance to 
development and survival (Saba-El-Leil et al., 2003). Signaling is initiated by a EGF binding to 
EGFR (RTK) on the surface of the cells which stimulates the conversion of GDP bound Ras to 
the active GTP bound Ras. Next, Raf family kinases (Raf-1, A/B/C Raf) phosphorylate MEK1/2 
at two sites (Fremin and Meloche, 2010). MEK1/2 then phosphorylates ERK1/2 at two sites via 
TEY motif. ERK1/2 then phosphorylates cytosolic substrates p90RSK, Elk-1, and Sapla. 
ERK1/2 also translocates to the nucleus and activate transcription factors related to proliferation, 
angiogenesis, and EMT (Lenormand et al., 1993, Yoon and Seger, 2006, Pecorino, 2016). 
Approximately 50% of ERK1/2 is found in the nucleus depending on the time after growth factor 
activation (Chen et al., 1992). In some cases the activation of ERK1/2 is transient (less than 20 
minutes) while in other scenarios its activation is sustained (greater than 3 hours) (Wortzel et al., 
2011). 
Activating mutations KRAS and BRAF are observed in 30% and 20% of all cancers, 
respectively (Downward, 2003, Fremin and Meloche, 2010). More specifically, KRAS mutations 
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are observed in bladder, breast, colon, kidney, lung, hematopoietic malignancies, ovarian, and 
thyroid cancers. KRAS activates growth factors such as EGFR and ERBB2 (Downward 2003). 
Clinically, many approaches using Receptor Tyrosine Kinase inhibitors (RTKis) have been used 
in KRAS mutant cancers. BRAF on the other hand has been successfully targeted in V600E 
mutant melanoma. Downstream of Raf, MEK1/2 or ERK1/2 overexpression in mouse models led 
to aggressive tumors and increased metastasis (Fremin and Meloche 2010). Preclinical tumor 
models with BRAF mutations revealed that MEK1/2 inhibition reduced tumor volume and 
metastasis. Furthermore, the MEK1/2, Trametinib, is FDA approved to treat BRAF mutant 
melanoma and other cancers (FDA reference ID: 4255758) 
 
Figure 1-10. BRAF mutation frequency in cancer. Adapted from Bailey et al., 2018. 
 
In breast cancer estrogen has been shown to modulate ERK1/2 via cSrc (Yi et al., 2013). 
Additionally, ERK1/2 was observed to activate the estrogen receptor via p90RSK, which 
resulted in increased transcriptional efficiency of ER, related genes (Santen et al. 2002, Neuzillet 
et al., 2014). Although KRAS and BRAF are common mutations in cancer, they are relatively 
rare in breast cancer with 1.5% and 3% incidence, respectively (Saini et al., 2013). Although 
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MEK1/2 and ERK1/2 are not mutated in breast cancer they still play an important role. For 
example, ERK1/2 overexpression in TNBC patients was correlated with a worse survival rate 
(Bartholomeusz et al., 2012). In IDCs, both in vitro and in vivo ERK1/2 activation increased 
metastatic potential (Ma et al., 2012).  
 
Figure 1-11. Summary of MAPK Signaling. Adapted from Drew et al., 2012. Reproduced with 
permission; License number: 4570510965494.  
 
The MEK5/ERK5 pathway is a relatively recent discovery in the MAPK family and has 
several distinct features. In particular, ERK5 is structurally similar to ERK1/2 (50% sequence 
homology) but differs in size: 44/42 kD for ERK1/2 and 110 kD for ERK5. Hence ERK5 was 
aptly named “Big MAPK” or BMK-1 by Lee et al., 1995. ERK5 also has many similar functions 
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as ERK1/2 such as promoting survival, differentiation, proliferation, and development (Kato et 
al., 1997, Suzaki et al., 2002, Nishimoto et al., 2006, Li et al., 2008). In neurons ERK1/2 was 
observed to be active within minutes of BDNF stimulation while ERK5 was activated later and 
sustained activation for 24 hours (Cavanugh et al., 2001). ERK5 is ubiquitously expressed in 
cardiac myocytes, lungs, brain, and kidney (Lee et al., 1995, Zhou et al., 1995). ERK5 knockout 
in mice was embryonically lethal at day 10 and the mice were unable to form the neural crest 
(Hayashi and Lee, 2004, Drew et al., 2012). Ablation of the ERK5 gene also adversely affects 
the stability of the cardiovascular system due to compromised vascular integrity (Hayashi and 
Lee, 2004).  
Like the other MAPKs, MEK5/ERK5 is a three tiered kinase cascade and is activated by 
extracellular signals such as epidermal growth factor (EGF), neural derived growth factor 
(NDGF), cytokines, and oxidative stress. Upon activation, MEKK2 or MEKK3 phosphorylates 
MEK5 at two separate sites: Ser311 and Thr315 (Chao et al., 1999). MEK5 then phosphorylates 
ERK5 at the Thr218 and Tyr220 residues in the kinase domain. Once active by MEK5, ERK5 
undergoes a conformational change that exposes the nuclear localization domain (NLS) (Kondoh 
et al., 2006). ERK5 then translocates to the nucleus where it phosphorylates distinct targets (from 
ERK1/2): myocyte enhancer factor (MEF): MEF2A, MEF2C, and MEF2D (Kato et al., 1997). 
Activation of MEF genes are crucial for angiogenesis, endothelial cell survival, and heart 
development (Hayashi and Lee, 2004). The transcriptional activation domain, towards the C-
terminus, of ERK5 is unique and is required for phosphorylation of cFos and fos-related antigen-
1 (Fra-1) (Terasawa et al., 2003, Buschbeck and Ullrich, 2005). In contrast, ERK1/2 does not 
contain a NLS and enters the nucleus through three mechanisms: passive diffusion, active 
transport, or interaction with the nuclear pore complex (Knokhlatchet et al., 1998, Adachi et al., 
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1999, Matsubayashi et al., 2001). Also, ERK1/2 does not have a designated transcriptional 
activation domain and directly phosphorylates from the kinase domain (Nishimoto and Nishida, 
2006). Lastly, ERK5 phosphorylates many distinct cytosolic targets such as Bad (survival, serum 
regulated kinase (SGK, metabolism), and cMYC (proliferation) (Drew et al., 2012).  
MEK5/ERK5 signaling is altered in many cancer types and is considered an important 
factor in oncogenic signaling (Hoang et al., 2017). Overactive ERK5 signaling has been 
observed in cancers that overexpress receptor tyrosine kinases (RTKs) and is associated with a 
worse prognosis (Esparis-Ogando et al., 2002). The role of ERK5 in cancer has also been shown 
to be distinct from ERK1/2. For example, ERK5 expression was found to correlate with 
advanced tumor stage and lymphatic involvement in oral squamous cell carcinoma and not 
ERK1 (Sticht et al., 2008). Prostate cancer bone metastases with overexpression of MEK5 were 
associated with increased MMP-9 expression and a poorer prognosis (Mehta et al., 2003). 
Association of ERK5 and Focal adhesion kinase (FAK) has been correlated with increased 
cellular motility and metastasis (Sawhney and Brattian, 2009). In NIH3T3 fibroblast cells, ERK5 
activation mediated by Src overexpression led to increased invasion (Schramp et al., 2008).  
MEK5/ERK5 signaling also has many implications in breast cancer. High ERK5 (20%) 
expression was observed in high-grade ER- breast tumors and correlated with decreased disease 
free survival (Hsieh et al., 2005). ERK5 has also been linked to Breast tumor kinase (Brk) which 
is overexpressed in 86% of IDCs (Drew et al., 2012). In MDA-MB-231 (TNBC) cells ERK5 
mediated proliferation via cyclin dependent kinase 1 (CDK1) and p21 expression (Perez-
Madrigal et al., 2012). 
The tools for studying MEK5/ERK5 are currently limited to small molecule inhibitors 
and genetic ablation with shRNA or Crisper/Cas-9 knock out (KO). The inhibitors of MEK5, 
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BIX02188 and BIX02189, are ATP competitive inhibitors with cell free IC50 values of 4.3 nM 
and 1.5 nM, respectively (Tatake RJ, et al., 2008). XMD8-92 has been show to inhibit ERK5 
(downstream of MEK5) with a cell free IC50 of 80nM (Yang et al., 2010). However, recent 
studies have demonstrated XMD8-92 is also an inhibitor of BRD4 (an epigenetic regulator) with 
an IC50 of 190 nM. Therefore, AX15836 was developed as a selective, ATP competitive ERK5 
inhibitor with a cell free IC50 of 8 nM vs ERK5 and 3,600 nM vs BRD4 (Lin EC et al., 2016). 
siRNA for ERK5 decreased proliferation and mitotic entry in SNU449 hepatocellular carcinoma 
cells (HCC) (Zen et al., 2009, Lochhead et al., 2016). However BIX02189 was not able to 
recapitulate the siRNA effects in the same HCC cells (Lochhead et al., 2016). ERK5 knock down 
alone was not sufficient to decrease proliferation of lung, multiple myeloma (MML), and 
chromic myeloid leukemia (CML). However, combinations of ERK5 knock down with 
conventional therapy were effective (Wang et al., 2014). ERK5 knock down or inhibition 
combined with Doxorubicin for enhanced efficacy in lung cancer (Shukla et al., 2013). 
Additionally, dominant negative forms of ERK5 in MML and CML combined with the 
proteasome inhibitor Bortezombi and BCR-Abl tyrosine kinase inhibitor Imatinib for increased 
in vitro efficacy (Buschbeck et al. 2005, Carvajal-Vergara et al. 2005). Taken together, these 
studies implicate MEK5/ERK5 as an important mediator of various oncogenic processes such as 
proliferation and survival. Additionally, the MEK5/ERK5 pathway also has a key role in 
tumorgenesis and drug resistance. Although initial studies with MEK5/ERK5 inhibition or 
genetic ablation have shown promise, there is a need for new tools to study this pathway.  
 
 




The PI3K/Akt/mTOR pathway is an evolutionarily conserved signal transduction 
pathway that is responsible for many crucial cell functions, such as metabolism, motility, 
survival, and proliferation (Cantley 2002, Goncalves et al. 2019). Activation of the pathway is 
initiated by extracellular growth factors and cytokines that bind to RTKs and GPCRs. Signal is 
transduced intracellularly beginning with Phosphoinositide 3-Kinase (PI3K) which converts 
Phosphatidylinositol (4,5)-bisphosphate (PIP2) to Phosphatidylinositol (3,4,5)-triphosphate PIP3. 
The conversion of PIP2 to PIP3 is facilitated by the catalytic subunit of PI3K p110 (Gomparts et 
al. 2009). There are four isoforms of p110 and many are investigated for therapeutic 
intervention. Once PIP3 is formed, it phosphorylates PDK1, which in turn phosphorylates Akt 
(also known a protein kinase B; PKB) at the threonine 308 residue (Cantley 2002). Akt then 
phosphorylates mTOR, which subsequently phosphorylates Akt at the serine 473 residue (Cidado 
and Park 2012). Activated Akt then phosphorylates a multitude of targets that influence cellular 
functions: p27 (cell cycle), glucose transporters  and GSK3B (metabolism), Forkhead box 
(FOXO) and Bad proteins (survival and apoptosis) (Hemming and Restuccia 2012, Costa et al. 
2018). The PI3K/Akt/mTOR pathway is mainly regulated by two phosphatases: PP2A and 
PTEN. PP2A dephosphorylates Akt at both T308 and S473 residues (Hemming and Restuccia 
2012). PTEN inhibits the conversion of PIP2 to PIP3 (Cantley 2002). Therefore, a loss or 
downregulation of PTEN frequently leads to hyperactivated Akt signaling due to increased PIP3 




Figure 1-12. Summary of PI3K/Akt/mTOR signaling. Adapted from Carnero and Paramino 
2014. 
 
 The PI3K/Akt pathway is frequently altered in cancer and mutations in this pathway are 
considered oncogenic driver mutations due to their crucial role in cellular functions. PIK3CA 
(encodes for the p110 alpha isoform of PI3K) mutations occur on the catalytic subunit of p110. 
More specifically these mutations predominantly affect the alpha isoform (Figure 1-13). 
Mutations in the catalytic domain confer constitutive activity of the PI3K pathway and have been 
observed in brain, breast, colon, liver, lung, and ovarian cancers. Additionally, mutations of the 
downstream kinase Akt (E17K) have also been observed in breast, brain, lung, and bladder 
cancers (Hyman et al. 2017). Lastly, alterations in the tumor suppressor PTEN appears in about 
15% of all cancers (Baliey et al. 2018). PTEN alterations are variable in mechanism: loss of 
function point mutation, hetero or homozygous deletion, degradation, miRNA, or epigenetic 
suppression (McCubrey et al. 2012). In breast cancer, PTEN alterations are as a whole (3% of 
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cases) but in TNBC 35-50% of patients harbor PTEN alterations (Saini et al. 2013). Several 
PI3K/Akt/mTOR inhibitors are currently under clinical evaluation in TNBC (Table 1-2). 
  
Figure 1-13. PIK3CA mutation frequency in cancer. Adapted from Bailey et al. 2018. 
 
Compound Target(s) Study Phase Trial ID 
Alpelisib PI3K∝ 2 NCT02506556 
Taselisib PI3K (𝛽 sparing) Ib/2 NCT02457910 
MK2206 Pan Akt (allosteric) 2 NCT01277757 
Ipatasertib Pan Akt (ATP-comp) 2 NCT02301988 
Temsirolimus mTOR I NCT01111825 


















1.1.7 Crosstalk between MEK5/ERK5 and PI3K/Akt pathways  
 
 Crosstalk is defined, as the combined signal from two pathways is different than each 
pathway alone. The two pathways can be directly or indirectly related. For example if one 
pathway is modified directly by another pathway (e.g. phosphorylation) then the pathways are 
directly related. Examples of direct crosstalk are crossactivation via phosphorylation and 
convergence on a single target at separate phosphorylation sites. Additionally, a pathway may 
indirectly influence another by altering gene expression (Vert and Chory 2011).  
MEK5/ERK5 and PI3K/Akt crosstalk is less studied than MEK/Akt crosstalk. However 
reports of crossactivation and points of signaling convergence have underscored its importance 
in oncogenic signaling. For example, genetic ablation of Akt in neuroblastoma cells led to a 
decrease in ERK5 phosphorylation. Also, Akt was shown to phosphorylate MEKK3, the 
upstream kinase of MEK5 (Umapathy et al. 2014). In our preliminary studies, we observed 
similar results: the Akt inhibitor Ipatasertib decreased phosphorylated ERK5 in U87 
glioblastoma cells (Figure 1-14). U87 cells are PTEN mutant and have hyperactive Akt. 
Therefore, the crossactivation of MEK5/ERK5 via Akt is likely to be present in cancers with 
similar PTEN alterations. In addition to crossactivation, both MEK5/ERK5 and PI3K/Akt have 
been shown to converge on the survival proteins Bad and FOXO3a (Pi et al. 2004, Drew et al. 
2012). In particular Akt has been shown to phosphorylate Bad at Ser136 while ERK5 
phoshorylates Bad at Ser112 (Datta et al. 1997, Pi et al. 2004). Interestingly, both pBad S112 and 
S136 expression was shown to be higher in the TNBC cell line MDA-MB-231 vs the normal 
tissue cell line MCF-10A (Sickels et al. 2015). Therefore, targeting both MEK/ERK5 and 
PI3K/Akt in a serial rather than parallel manner will perhaps yield effective and less-toxic results 
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(Yin et al., 2014). Figure 1-15 summarizes the known crosstalk between the MEK5/ERK5 and 
PI3K/Akt pathways.  
 
 
Figure 1-14. Akt inhibitor Ipatasertib decreases pERK5 in PTEN mutant GBM cells. U87 
glioblastoma cells were treated with Akt inhibitor Ipatasertib for 1 hour prior to 5% FBS 
stimulation for 24 hours. DMSO has used as a vehicle control. Cellular lysates were collected 
and proteins were visualized via western blot.  (Seraina Schottland, Unpublished work) 
 
Figure 1-15. Akt crossactivation of MEK5/ERK5 pathway. 
Summary of MEK5/ERK5 and Akt crosstalk: (1) Akt crossactivation of MEKK3 (2) 




1.2 Statement of the problem 
 
Breast cancer is a heterogeneous disease and according to the American Cancer Society, 
250,000 new cases are reported annually. Breast cancer is the second leading cause of cancer 
death in women with 40,000 deaths annually. The majority of breast cancer mortality is 
attributed to invasive disease. In particular, Invasive Ductal Carcinomas (IDC) make up over 
80% of all invasive cases (Allred 2010). IDCs are primarily categorized by hormonal profile. 
IDCs that express ER+ and HER2+ are responsive to endocrine therapy and have a favorable 
prognosis. However, endocrine resistance remains a major challenge to treating ER+ and 
HER2+. Triple-negative breast cancers (TNBCs) are a type of IDC that lack hormone receptors. 
TNBCs are not responsive to chemotherapy and have the poorest prognosis of IDCs. TNBCs are 
primarily treated with chemotherapy and no targeted treatment is available.  
Recent advances in genomic screening have yielded promising leads for targeted therapy 
in cancer. For example, the discovery of the V600E BRAF mutation led to the development of 
agents that target the Raf/MEK/ERK axis in BRAF mutant cancers. However, not all cancers 
have been successfully treated with targeted agents and there is a need to investigate unique 
signaling pathways that contribute to oncogenic phenotypes. The MEK5/ERK5 pathway is a less 
studied member of the MAPK family and has a role in the oncogenic signaling of many cancer 
cell types (Hoang et al. 2017). Additionally, MEK5/ERK5 has been shown to interact with other 
“driver” cancer pathways such as PI3K/Akt (Umapathy et al. 2014). Therefore, we propose the 
study of MEK5/ERK5 signaling in a variety of breast cancer cell lines: both hormonally diverse 






1.2.1 Research Objectives 
 
1.2.2 Hypotheses and Research Aims 
 
1a). Combination of Akt and ERK5 inhibition will more effectively decrease MDA-MB-
231 TNBC viability, proliferation, and migration than either inhibitor alone. 
 
1b). Ipatasertib plus XMD8-92 will decrease viability proliferation, and migration in 
PTEN mutant TNBC cell lines MDA-MB-468 and BT549 than either drug alone. 
 
2). Novel diphenylamine derivatives will provide selective inhibition of the MEK5/ERK5 
pathway in MDA-MB-231 TNBC cells. 
 
3). The combination of Akt and ERK5 inhibition will reduce proliferation in an acquired 


































Chapter 2: Materials and Methods 
 
 
2.1 Cell culture  
 
Human breast cancer cell lines were obtained from ATCC (Manassas, VA) and 
maintained in accordance with the manufactures’ instructions (Table 2-1). Cell lines were 
selected based on hormone and genetic profiles (Table 2-1). The human triple-negative breast 
cancer cell line MDA-MB-231 was obtained from ATCC and was maintained in DMEM:F-12 
(1:1) (Life Technologies), 10% Fetal Bovine Serum (Atlanta Biologicals), and 1% 
Penicillin/Streptomycin (Sigma). The MCF-10A cell line was also obtained from ATCC and was 
used as a normal tissue control. Each cell line was utilized for fewer than 15 passages after 
thawing except for the MCF-7 and TamR cell lines which were both passaged approximately 50 
times over a 6 month period.  
 
Table 2-1. List of cell lines and cell culture conditions.  


































BT549 Breast Triple 
negative 
1640 RPMI, 










L-15, 10% FBS, 







MCF-7 Breast ER+ 1640 RPMI, 







MCF-7 Breast ER+ 1640 RPMI (- Metastasis, CDKN2A and 
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TamR Phenol Red), 








BT474 Breast Triple 
positive 
Hybricare, 10% 








N/A MEM Bullet Kit, 
2.5% FBS, and 
5% CO2 
N/A N/A 
U87-MG Glioblastoma N/A MEM, 10% 







2.1.1 Generation of MDA-MB-231 ERK5 KO cells  
 
MDA-MB-231 ERK5 KO cells were generously gifted by Dr. Matthew Burow’s 
laboratory (Tulane University, New Orleans, LA). The Burow lab employed a pU6 driven guide 
strand with dual expression cassettes for Cas9/EGFP plasmids based approach (Horizon, 
Cambridge, UK). Using 5 individual guide strands targeting exons 3 and 5 of the MAPK7 gene 
they transfected TNBC (MDA-MB-231) cells. After 24 hours, cells were FACS for EGFP 
expression and plated for stable colony formation. The purity of ERK5 KO was determined by 
western blot analysis of ERK5 expression. 
2.1.2 Generation of tamoxifen resistant MCF-7 cells 
 
TamR cells were established as described in Rabenoelina et al. 2002. In brief, MCF-7 
cells were treated with 100 nM 4-OH Tamoxifen (Sigma) in phenol red free medium with 
charcoal stripped FBS for 6 months. Resistance was established by assessing sensitivity to 4-OH 
Tamoxifen (MTT assay), proliferation (Ki67 staining), radioligand binding of Estrogen to 





2.2 Cell viability  
 
Cell viability was determined using the MTT assay. Breast cancer cells were plated at a 
density of 5x103 cells per well (96 well plate). Cells were allowed to attach overnight and were 
treated with inhibitors alone or in combination with 5% FBS stimulation for 72 hours. DMSO 
was used as a vehicle control. After treatment, 10µL MTT (Sigma) was added to each well (0.5 
mg/mL final concentration) and the plates were incubated for 3 hours (5% CO2 and 37℃). The 
medium was removed and the MTT-formazan crystals were dissolved with 100µL DMSO per 
well. Absorbance was measured at 570 nm with a VICTOR3 1420 multilabel counter (Perkin 
Elmer). Three wells were analyzed for each condition, and wells containing medium-MTT only 
(no cells) and vehicle were used as controls. IC50 values from the MTT experiments were 
calculated with Microsoft Excel. 
 
2.3 Western blot analysis 
 
Protein levels of ERK1/2, ERK5, Akt and apoptotic markers were measured using 
western blot. Cells were plated at a density of 5x105 per well (6 well plate). Cells were allowed 
to attach overnight and then serum starved for 24 hours before treatment. Cells were treated with 
vehicle or inhibitors one hour prior to 5% FBS stimulation for 24 hours. For Bad signaling, 
50ng/mL EGF for 4 hours was used as a stimulus. Following treatment, cells were lysed and 
protein content was determined by a Bradford assay (Bio-Rad). 30µg of protein was loaded on a 
4-15% SDS-PAGE gradient gel (Bio-Rad). The contents of the gel were transferred to a 
membrane and then probed with various antibodies: anti-phospho-ERK1/2, anti-total ERK1/2, 
anti-total ERK5, anti-phospho-ERK5, anti-phospho-Akt (Ser 473), anti-Akt, anti-pS6 (Ser 
240/244), anti-p21, anti-cMYC, anti-Bad, anti-phospho-Bad (Ser112, Ser136), and anti-Cleaved 
PARP (1:1,000, Cell Signaling). Anti-GAPDH (1:10,000; Millipore) was used as a loading 
 
 33 
control. The binding of antibody to antigen was detected by incubating membranes with 
secondary antibodies and scanning on an Odyssey Infrared Imager (LICOR biosciences). Blots 
were analyzed using ImageStudioLite by a blinded observer (LICOR biosciences). Phospho-Bad 
Ser112 was quantified with PathScan ELISA (Cell Signaling; 7182C) with the same lysates used 
in western blot analysis.  
 
2.4 Invasion/ Migration 
 
2.4.1 Scratch Assay 
 
Cell migration was measured using the “scratch” wound healing assay. Cells were seeded 
at a density of 200,000 cells/well in a 12 well plate. Cells were allowed to attach and grow to 
70% confluence. Prior to treatment, the medium was removed and a “scratch” was made with a 
200 𝜇L pipet tip. The underside of the plate was marked to denote the location of the initial 
wound. Detached cells and debris were washed off and removed with 1x PBS. After the wash, 
treatments were added to each well and initial images were obtained with an EVOS-fl inverted 
microscope under 10x magnification. The assay was ended with images were obtained after 24 
hours. Wound closure was calculated by the formula:  (border at 24 hr – border at 0 hr)/(border 










2.4.2 Invasion assay 
 
Cell invasion was assessed using a basement membrane invasion assay. A Boyden 
chamber with 12 basement membrane inserts were brought to room temperature for 10 minutes 
and were rehydrated with 300 𝜇L base medium with no FBS for 1 hr. The media was removed 
prior to adding 270 𝜇L of the cell suspension in base medium with no FBS (125,000 cells/well) 
and 30 𝜇L of the 10x inhibitor solution (1:10 dilution will make 1x final concentration) to the 
basement membrane insert. 500 𝜇L of the base medium plus 10% FBS was added to the bottom 
layer. The plate was incubated for 48 hours. The medium was aspirated from the inner layer and 
the insert was transferred to a well with 225 𝜇L of cell detachment solution for 30 minutes at 
37℃. 75 𝜇L of the Cytoquant/4x Lysis buffer solution was added to each well and incubated for 
20 minutes at room temperature 200 𝜇L of the resulting mixture was transferred to a blacked out 
Fluorescence plate and measured at 485 nm using a micro plate reader. Three wells were 




ELISA assays were conducted for Cleaved caspase-3, pBad S112, PTEN, and ER-ERE 
complexes. Breast cancer cells were treated with inhibitors for 48 hours then lysed in accordance 
with the PathScan Sandwich ELISA (Asp 175) protocol (Cell Signaling; 7190C). The 
absorbance was measured at 450 nm with a VICTOR3 1420 multilabel counter (Perkin Elmer). 
Three wells were analyzed for each condition and the results were normalized to lysate protein 
concentration. 
 2.5.1 Cleaved caspase 3 Cell Signaling #7190C 
 
 2.5.2 ERE Active Motif 
 




 2.5.4 PTEN Cell Signaling #7882C 
 
2.6 Immunofluorescence  
 
Cellular proliferation and morphology were visualized with immunofluorescence. Cells 
were plated and treated as described in the MTT assay. After treatment, cells were fixed in 4% 
paraformaldehyde for 15 minutes. Cells were then permeabilized with 0.3% Triton-X followed 
by the addition of rabbit Ki67 and mouse ∝-Tubulin primary antibodies (1:1000, Cell Signaling). 
Goat anti-mouse Alexa Flour 488 nm and goat anti-Rabbit Alexa Flour 555 nm (1:1000, 
Invitrogen) were used as secondary antibodies. A Hoechst (Fisher) stain was used to visualize 
the nucleus. Images were obtained with an EVOS fl inverted microscope (Life Technologies) 





Various inhibitors of the MEK1/2/ERK1/2, MEK5/ERK5, and PI3K/Akt pathways were 
selected due to their potencies (Table 2-2). Additionally, the microtubule inhibitor paclitaxel and 
ER antagonist tamoxifen were used for select experiments (Table 2-2). All inhibitors were 
dissolved in DMSO (Fisher) and used in the concentrations noted in the text and figures. Control 
groups were treated with a percentage of DMSO (0.2% maximum in combination groups) equal 







Table 2-2. List of known compound target(s) and potencies. 
Compound Target(s) Potency 
(IC50) 
Reference(s)  
XMD8-92 ERK5 and BRD4 80, 190 nM Yang et al. 2010; Lin EC et al. 2016 
AX15836 ERK5 8 nM Lin EC et al. 2016 
U0126 MEK1/2 60, 70 nM Duncia et al.1998 
Trametinib MEK1/2 0.92, 1.8 nM Yamaguchi et al. 2011 
CPI-203 BRD4 37 nM Ballachanda et al. 2012 
LY294002 Pan PI3K 500-570 nM Chaussade et al. 2007 
Ipatasertib Akt 1/2/3 5, 18. 8 nM Kui et al. 2012 
4-OH 
Tamoxifen  
ER alpha 2-10 nM Horwitz et al. 1978 
Paclitaxel Microtubule 0.1 pM Wang et al. 2003 
Temozolomide Alkylating agent Variable  Lee 2016 
VO-Ohpic 
trihydrate 
PTEN 35 nM Rosivatz et al. 2006 
 
2.8 Colony formation 
 
Three dimensional cell growth was assessed using a Soft Agar Colony Formation assay 
(Cell Biolabs: CBA-130). 1×104 MDA-MB-231 cells were mixed with a 1.2% agar solution in 
growth medium (5% FBS) for a final concentration of 0.4% agar. The cell mixture was plated on 
top of a solidified base agar layer. Inhibitor solutions were added on top of the cell layer and 
colonies were allowed to grow for 7 days. The contents from each well were solubilized and 
quantified according to the manufacturer’s instructions. Fluorescence was measured at 485 nm 
with a VICTOR3 1420 multilabel counter (Perkin Elmer). Three wells were analyzed for each 
condition (n=3). 
2.9 Synergy calculations 
 
Cell viability data from the MTT assay were analyzed for synergy using the Chou Talalay 
method (1984). Individual concentration response curves were compared to 1:1 and 1:3 
combinations of Ipatasertib:XMD8-92. Combination indexes (CI) were obtained and CI<1 were 




2.10 Statistical inference  
 
The data are presented as the mean +/- SEM of at least three independent experiments run 
in triplicate (n=3). Results were analyzed using Graph Pad Prism software (La Jolla, CA). Data 
were compared to respective controls with a One-Way ANOVA (Boferroni post hoc analysis), 






















Chapter 3: Evaluation of PI3K and ERK5 inhibition in hormonally diverse breast cancer 
3.1 Introduction  
Breast cancer is a heterogeneous disease state that is primarily characterized by hormonal 
profile. The majority of breast cancers are estrogen receptor (ER) positive (30-40%) and, HER2 
positive (25%) (The cancer genome atlas 2012). In some cases, breast cancer is characterized as 
triple positive meaning it has receptors for ER, PR and HER2. The standard of care for hormone 
positive breast cancers is endocrine treatment via hormone receptor antagonists or antibodies. 
Even though response rates to endocrine therapy are high, relapse and resistance remain a 
problem and drive mortality (Ali et al. 2016). Resistance is in many cases is attributed to genetic 
aberrations in survival pathways that confer an advantage for survival. Breast cancers that lack 
hormone receptors are called triple-negative breast cancer (TNBC). TNBCs constitute 10-15% of 
all invasive breast cancers and are associated with a poorer prognosis (Chavez et al. 2010). The 
mainstay of TNBC is chemotherapy and radiation (MD Anderson Manual of Medical Oncology, 
2016). With no targeted therapy for TNBC, there is an opportunity to explore MAPK and Akt as 
possible candidates for targeted treatment. In summary, targeting MAPK and Akt aberrations in 
hormonally distinct breast cancer could have applications for treatment-resistant ER+ breast 
cancer and TNBC.  
The prevalence of genomic aberrations in the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK 
pathways have been demonstrated to be key drivers of cancer cell signal transduction (Bailey et 
al. 2018). With respect to breast cancer, PI3K/Akt mutations are prevalent in certain subtypes: 
PIK3CA 40% of luminal A and B (ER+), 7% Basal Triple-negative, and 42% HER2 triple 
positive. PTEN 19% in luminal A and B (ER+), 35% Basal Triple-negative, 19% HER2 triple 
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positive (The cancer genome atlas 2012). Ras/Raf/MEK/ERK mutations: MAP3K1 14% and 5% 
of luminal A and B, KRas 1.5% of all breast cancer, BRaf 3% of all breast cancer (Santarpia et 
al. 2012). Although rarer, the MEK/ERK aberrations are more common in triple-negative and 
basal subtypes.  
Monotherapy against either MAPK or PI3K/Akt has been extensively studied in breast 
cancer with limited success (Saini et al. 2013). Therefore, combinations of PI3K or Akt and 
MEK or ERK inhibition were tried in hopes of improved efficacy. However, these pre-clinical 
studies and clinical trials yielded results less efficacious than expected (Saini et al. 2013). Many 
combination trials were terminated due to high collateral toxicity. For example, GDC-
0941(PI3K) plus GDC-0973 (MEK1/2) NCT00996892 Phase I study was terminated early due to 
high grade (3 and 4) toxicities of diarrhea and ocular toxicity. Hyperglycemia is a “class effect” 
of PI3K inhibition since it decouples PI3K from the insulin receptor and does not allow for 
glucose to be uptaken into the cells (Moreno et al. 2011). Lastly, pan-isoform PI3K inhibition 
can anemia due to the inhibition of the delta isoform with is a key factor in blood cells 
(neutropenia). In response, isoform specific Inhibitors of PI3K such as Taselisib (PI3K, 𝛽 
sparing) and Idelalisib (PI3K delta) were developed. Taselisib is currently in phase III trials for 
breast cancer. Idelalisib is FDA approved for treating hematopoietic malignancies such as 
Chronic Lymphoblastic Leukemia (CLL) (Godbersen et al. 2014). The MEK induced retinopathy 
is a particular “class effect” of MEK1/2 inhibition (Houede et al. 2011, Stjepanovic et al. 2016). 
MEK signaling maintains the retinal pigment epithelium (RPE) integrity and protects the RPE 
from oxidative stress, light induced damage and inflammation (Jiang et al. 2009). Clinically, 
MEK inhibition manifests as retinal detachment and periorbital edema (Stjepanovic et al. 2016). 
In a phase 1b trial of selumetinib (MEKi) and MK2206 (Akti) the combination group reported 
 
 40 
multiple cases of serous retinal detachment (Tolcher et al. 2011). Therefore there is a need to 
utilize other inhibitory patterns in hopes of better efficacy and lowered toxicity. 
As mentioned above, the combination of inhibitors for MEK1/2 and PI3K have been 
studied extensively in various cancers; however, PI3K inhibitors combined with MEK5/ERK5 
inhibition has not been extensively explored in breast cancer. The MEK5/ERK5 pathway is a 
novel, interesting target because of its diverse roles in the cell. For example, in estrogen positive 
cancer ERK5 localizes to the nucleus and aids in gene transcription. Whereas, in hormone-
independent cancer, ERK5 localizes to the cytosol and is involved in epithelial to mesenchymal 
transition (EMT) and metastasis (Madak-Erdogan et al. 2014). Moreover, investigations of the 
role of the MEK5/ERK5 pathways in breast cancer, and cancer in general are limited. One 
inhibitor for ERK5, XMD8-92, was well tolerated in vivo (Yang et al. 2010) and will be used 
through out this study. The results of the current study will add to our understanding of the role 
of this novel pathway in cancers and provide a foundation for the development of novel 
therapies. 
 
3.2 Hypothesis  
Dual inhibition of the PI3K/Akt and MEK5/ERK5 pathways will decrease viability and 
migration in a panel of hormone receptor diverse breast cancers. 
3.3 Results  
3.3.1 MDA-MB-231 (TNBC cell line) 
First, the MDA-MB-231 TNBC cell line was selected due to its prominence in the 
literature and unique mutational profile (Chavez et al. 2010). The MDA-MB-231 cell line has a 
BRAF and KRas “driver mutations” which is crucial for ERK1/2 signal activation. Interestingly, 
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the MDA-MB-231 cell line is relatively insensitive to MEK1/2 inhibition, in cell culture, despite 
its BRAF and KRas driver mutations (Hollestelle et al. 2009). Therefore, we propose that sparing 
ERK1/2 signaling in MDA-MB-231 cells will not affect the efficacy of MEK5/ERK5 and 
PI3K/Akt dual inhibition.   
The PI3K inhibitor LY294002 significantly decreased MDA-MB-231 cell viability in a 
concentration dependent manner beginning at 1  𝜇M (75% viability) to 100  𝜇M (6% viability) 
(Figure 3-1A). The MTT IC50 was determined to be 13.8 𝜇M for LY294002 (Figure 3-2A). The 
MEK1/2 inhibitor U0126 significantly decreased cell viability beginning at 3  𝜇M (75% viability) 
however was unable to further reduce viability even at 100  𝜇M (72% viability) (Figure 3-1B). 
The lack of MEK1/2 inhibitor efficacy was interesting since MDA-MB-231 cells harbor a BRAF 
driver mutation. However, these results are consistent with previous reports that MDA-MB-231 
cells are relatively resistant to MEK1/2 inhibition in 2D culture (Mirzoeva et al. 2009).  Lastly, 
the ERK5 inhibitor XMD8-92 significantly reduced viability in concentration dependent manner 
from 3µM (70% viable) to 100µM (11% viable) (Figure 3-1C). The MTT IC50 was determined to 
be 31.3  𝜇M for XMD8-92 (Figure 3-2A). Both the IC50s, from the MTT assay, of LY294002 and 
XMD8-92 were confirmed with crystal violet staining followed by microscopy (Figure 3-2B). 
Once LY294002 and XMD8-92 potencies were established, we sought to investigate 
combinations with the aim of enhanced efficacy. We examined various inhibitor stoichiometries 
such as 1:1 and 1:3 ratios of LY:XMD. In our study, the 1:1 and 1:3 combinations of LY:XMD 
decreased viability starting at 3,3 (75% viable) and 5,5 (50%) 𝜇M for 1:1 and 1,3 (58% viable) 
for 1:3 ratio (Figure 3-3A). Additional analysis of the 5,5 𝜇M combination revealed that the 
combination reduced viability more than each drug alone (Figure 3-3B). Next, the migratory 
capacity of MDA-MB-231 cells was analyzed with the scratch/wound healing assay (Figure 3-
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3C). LY294002 alone decreased wound closure 47% while XMD8-92 decreased wound closure 
22% versus control. The 5,5  𝜇M LY+XMD combination decreased wound closure 36% versus 
control and was not significantly different than each drug alone. Lastly, kinase signaling was 
analyzed for each inhibitor condition. The ERK5 inhibitor, XMD8-92, decreased the ratio of 
phosphorylated to total (p/t) ERK5 alone (57% inhibition) and in combination with LY (79% 
inhibition) (Figure 3-4A). Neither LY294002 nor XMD8-92 alone or in combination inhibited 
ERK1/2 (Figure 3-4B). PI3K inhibitor, LY294002, decreased the ratio of p/t Akt alone (59% 
inhibition) and in combination with XMD8-92 (71% inhibition). The inhibitory actions of 




Figure 3-1. Evaluation of PI3K, ERK5, and MEK1/2 inhibitors in MDA-MB-231 triple-
negative breast cancer cells. MDA-MB-231 TNBC cells were treated with PI3K inhibitor 
LY294002 (A.), MEK1/2 inhibitor U0126 (B.), and ERK5 inhibitor XMD8-92(C.) for 72 hours 
under 5% FBS stimulation. Cell viability was determined using the MTT assay. DMSO was used 
as a vehicle control. Data represent Mean +/- SEM of three independent experiments run in 
triplicate (n=3). One-Way ANOVA analysis performed with GraphPad prism software. 





Figure 3-2. Determination of IC50 of LY294002 and XMD8-92 in MDA-MB-231 cells. MTT 
results from figure 1 were analyzed with Microsoft excel to determine IC50 values (A). MDA-
MB-231 cells were treated with IC50 concentrations obtained from MTT assay for 72 hours under 
5% FBS stimulation. Cells were fixed with 4% paraformaldehyde, stained with 0.1 % crystal 






Figure 3-3. Simultaneous ERK5 and PI3K inhibition decreased viability and wound closure 
in MDA-MB-231 cells. MDA-MB-231 were treated with various 1:1 and 1:3 combinations of 
LY:XMD for 72 hours under 5% FBS stimulation (A and B). Cell viability was determined using 
the MTT assay. MDA-MB-231 cells were treated with LY294002 and XMD8-92 alone or in 
combination for 24 hours under 5% FBS stimulation (C). DMSO was used as a vehicle control.  
Wound closure measured using the “scratch” assay. Data represent Mean +/- SEM of three 
independent experiments run in triplicate (n=3). One-Way ANOVA analysis performed with 
GraphPad prism software. *P<0.05,**P<0.01, and ***P<0.001 vs DMSO+FBS vehicle control. 





Figure 3-4. Combination of ERK5 and PI3K blockade inhibited respective targets while 
sparing ERK1/2 activity in MDA-MB-231 cells. Kinase analysis of LY+XMD 5  𝜇M each 
combination in MDA-MB-231 cells. MDA-MB-231 cells were treated with 5  𝜇M LY294002 and 
XMD8-92 alone ore in combination for 1 hour prior to 50ng/mL EGF stimulation for 24 hours. 
Western blot analysis was performed on cellular lysates. GAPDH was used as a loading control. 
ERK5 (A), ERK1/2 (B), and Akt (C) were quantified using Image Studio Lite. *P<0.05 and 








3.3.2 MCF-7 (ER+ cell line) 
 Next, the MCF-7 cell line was selected because of its ER+ status, luminal A suntype, and 
PI3K mutational status (Perou et al. 2000, Sorlie et al. 2001). As mentioned in the introduction, 
Akt can crossactivate the MEK5/ERK5 via MEKK3 phosphorylation (Umapathy et al. 2014). 
Therefore, we propose that cancers harboring PI3K and PTEN alterations perhaps activate the 
MEK5/ERK5 pathway and necessitate the inhibition of both pathways. Additionally, we also 
propose that dual MEK5/ERK5 and PI3K/Akt inhibition can be achieved with out disrupting 
MEK1/2/ERK1/2 signaling.   
In the MCF-7 cell line, the PI3K inhibitor LY294002 significantly decreased viability at 
5  𝜇M (58% viability; Figure 3-5A). The ERK5 inhibitor XMD8-92 also significantly decreased 
viability at 5  𝜇M although to a lesser degree than LY294002 (79% viability). In combination the 
viability was 45%, which was significantly less than both drugs alone (Figure 3-5A). With 
respect to migration, LY294002 and XMD8-92 decreased wound closure 60% and 45%, 
respectively. In combination the drugs decreased wound closure 80%, which was significantly 
greater than both drugs alone (Figure 3-5B). XMD8-92 decreased the ratio of p/t ERK5 alone 
(74% inhibition) and in combination (59% inhibition) (Figure 3-6A). Neither LY294002 nor 
XMD8-92 decreased the p/t ratio of ERK1/2 (Figure 3-6B).  Both LY294002 alone or in 
combination inhibited the p/t ratio of Akt by 97% (Figure 3-6C). XMD8-92 increased the p/t 






Figure 3-5. ERK5 and PI3K combination decreases viability and wound closure in 
Estrogen positive MCF-7 cells. MCF-7 cells were treated with 5  𝜇M LY294002 and XMD8-92 
alone or in combination for 72 hours under 5% FBS stimulation (A). DMSO was used a vehicle 
control. Cell viability was determined using the MTT assay. MCF-7 cells were treated with 
LY294002 and XMD8-92 alone or in combination for 24 hours under 5% FBS stimulation (B). 
Wound closure measured using the “scratch” assay. *P<0.05, **P<0.01, and ***P<0.001 vs 









Figure 3-6. Dual ERK5 and PI3K combination inhibits respective targets while sparing 
ERK1/2 activity in MCF-7 cells. MCF-7 cells were treated with 5  𝜇M LY294002 and XMD8-
92 alone ore in combination for 1 hour prior to 50ng/mL EGF stimulation for 24 hours. Western 
blot analysis was performed on cellular lysates. GAPDH was used as a loading control. ERK1/2 







3.3.3 BT474 (Triple positive cell line) 
Lastly, the cell line BT474 was evaluated due to is triple positive hormone profile, 
luminal B status and PI3K mutational status (Perou et al. 2000, Sorlie et al. 2001). In the 
viability assay, only the combination of LY+XMD decreased viability 51% (Figure 3-7A). 
Additionally, the scratch assay revealed interesting results with each of the compounds alone or 
in combination “widening” the initial wound (Figure 3-7B). Initial interpretations would be to 
assume that this was cell loss, however, these results appear to contradict the viability results 
where cell loss was only observed in the combination group. This could be due to an early loss of 
cells at the 24 hour time point as seen in the scratch assay and then the cells grow back in the 
single drug groups by the 72 hour mark and therefore the drugs appear to be ineffective. 
Alternatively, this could all be an artifact due to a surfactant effect. To account for this, we 
centrifuged our plates to pull down any floating cells that may still be viable. Concerning kinase 
activity, Only the combination of LY+XMD significantly the pERK5/tERK5 ratios compared to 
control (46% decrease Figure 3-8). pERK1/2/tERK1/2  ratios were unaffected in all three groups 
(Figure 3-8). The PI3K inhibitor LY294002 worked as expected and decreased pAkt/tAkt ratios 








Figure 3-7. ERK5 and PI3K combination decreases viability in triple-positive BT-474 cells. 
BT-474 cells were treated with 5  𝜇M LY294002 and XMD8-92 alone or in combination for 72 
hours under 5% FBS stimulation (A). DMSO was used as a vehicle control. Cell viability 
determined using the MTT assay. BT-474 cells were treated with LY and XMD alone or in 
combination for 24 hours under %5 FBS stimulation (B). Wound closure measured using the 




Figure 3-8. BT-474 cells western blot analysis. BT-474 cells were treated with 5  𝜇M 
LY294002 and XMD8-92 alone ore in combination for 1 hour prior to 50ng/mL EGF stimulation 
for 24 hours. Western blot analysis was performed on cellular lysates. GAPDH was used as a 
loading control. ERK5 (A), ERK1/2 (B), and Akt (C) were quantified using Image Studio Lite. 














3.4 Discussion  
 
The 5,5 𝜇M combination of LY+XMD reduced viability and migration in all three cell 
lines regardless of hormonal profile. In some cases the drugs were more potent alone such as 
LY294002 in the MCF7 cell line. This is logical because the MCF7 cell line has an E545K PI3K 
mutation that leads to constitutive activity and increased pAkt signaling (Wu et al. 2005)). 
Clinically evaluated compounds such as the Pan PI3K inhibitor Pictisilib have shown enhanced 
efficacy in the MCF7 cell line (Liu S et al. 2018). The 5,5 𝜇M combination also spared ERK1/2 
signaling in all three cell lines. These results were consistent with Yang et al. 2010 who found 
that concentrations of 5  𝜇M or less XMD8-92 did not inhibit ERK1/2 kinase activity. However, 
only one time point was tested, so it is possible there was transient inhibition or activation of 
ERK1/2 that was not detected. Therefore, in chapter 4 we will use additional time points to fully 
characterize the ERK1/2 phosphorylation state over time. Interestingly, the signaling produced in 
MDA-MB-231 and MCF-7 cells was similar: both phosphorylated and total Akt levels increased 
under XMD8-92 inhibition. Perhaps this is a compensatory pathway as described in (Umapathy 
et al. 2014) where the inhibited ERK5 pathway signals to Akt to upregulate and then reactivate 
MEK5/ERK5 via MEKK2 phosphorylation. This is also evidenced by the MCF-7 viability data 
where XMD only reduced viability by 21% alone, perhaps the increase in Akt reduced the effects 
of XMD. Therefore both PI3K and ERK5 need to be inhibited for efficacy. 
Further characterization is needed to determine if the PI3K and ERK5 inhibitor 
combination is synergistic. Similar studies of dual Akt and MEK inhibition demonstrated 1:2, 
and 1:4, and 1:8 ratios of Akt:MEK inhibition were effective in a panel of Non-small cell lung 
cancer (NSCLC) cell lines (Meng et al. 2010). Therefore, we will expand our study in the next 
chapter to encompass staggered ratios of PI3K/Akt to MEK5/ERK5 inhibition. Also, we will 
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continue to monitor the role of ERK1/2 because sparing its activity may be key to limiting 
toxicity. This is partiucally important since many combination trials with MEK inhibition have 
been halted due lack of efficacy, and high incidence of adverse events (NCT01907815, 
NCT00996892).  However, it is possible that sparing ERK1/2 activity may enhance invasion, 
which has been reported in breast cancer both cell lines and in patients (Barholomeusz et al. 
2012, Ma et al. 2012). Therefore, we will monitor the invasive potential of combination treated 
cells in chapter 4 to ensure the combination does not enhance invasion by sparing ERK1/2 

































Chapter 4: Evaluation of clinically relevant Akt inhibitor Ipatasertib in  
 




  To determine if the LY+XMD combination synergistically inhibits TNBC cell viability, a 
therapeutically relevant Akt inhibitor, Ipatasertib (GDC-0068; Ipat), was investigated. Ipatasertib 
is currently in a Phase III trial for patients with PI3K/ATK1/PTEN altered TNBC 
(NCT03337724), thus a primary reason why it was included in our study. Ipatasertib is more 
effective in pAkt high (low PTEN or Akt mutant) environments because it binds to Akt in the 
ATP site in the active from (Kui et al. 2012). The resulting Akt inhibition decreases 
phosphorylation of downstream targets: S6 ribosomal protein, Bad, and FOXO3a (Kui et al. 
2012, Lin J et al. 2013). In addition to promising pre-clinical results, Ipatasertib was well 
tolerated in combination with the MEK inhibitor GDC-0973 in a phase I clinical trial 
(NCT01562275). The trial yielded less severe toxicities than previous MEK+PI3K/Akt 
combinations: GDC-0973 (MEK) combined with GDC-0941 (PI3K) (NCT00996892). For 
example, Ipatasertib treated patients did experience the “class effects” of PI3K/Akt inhibition 
which included transient hyperglycemia and low grade (1 and 2) GI upset. This was in contrast 
to PI3K inhibition that produced sustained hyperglycemia, increased insulin levels, and severe 
colitis. Therefore, Ipatasertib appears to display an improved “class effect” profile compared to 
clinically investigated PI3K inhibitors. This is a key factor in ensuring the tolerability of Akt 
inhibition in a patent population. Even though Ipatasertib had fewer side effects than its PI3K 
predecessors, the combination trial phase 1b with MEK1/2 inhibition was not progressed to 
phase 2. This was primarily due to lack of efficacy and “class effect” ocular toxicity from 
MEK1/2 inhibition persisted in several patients: 14% on 300mg GDC-0973 and 33% on 400mg 
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GDC-0973 (NCT01562275).  Therefore, we propose our strategy of sparing MEK1/2 will help 
reduce toxicity.  
 
4.2 Hypothesis  
 
Combination of ERK5 inhibitor XMD8-92 with clinically relevant Akt inhibitor Ipataserib  
 
will decrease viability, colony formation, and migration in MDA-MB-231 TNBC cells.  
 
 
4.3 Results  
 
4.3.1 Ipatasertib in MDA-MB-231 WT 
 
In chapter 3, the PI3K inhibitor LY294002 in combination with the ERK5 XMD8-92 
signifcantly reduced viability in MDA-MB-231 cells. However, issues with PI3K inhibitor 
toxicity at the clinical level prompted us to use a more relevant and translatable inhibitor. As 
previously stated, Ipatasertib was tolerated better than PI3K inhibitors and is currently under 
investigation in TNBC. Therefore, we investigated Ipatasertib in combination with XMD8-92 in 
MDA-MB-231 TNBC cells. 
Ipatasertib, binds to Akt in the active conformation. This conformation protects the 
Thr308 and Ser473 phosphorylation sites from becoming dephosphorylated by the phosphatase 
PP2A. Therefore, pAkt is observed in the presence of Ipatasertib (Kui et al. 2012). In our study, 
the efficacy of Ipatasertib was determined by measuring phosphorylation of the ribosomal 
protein S6 (pS6; Ser 240/244), a downstream target of Akt. As expected, Ipatasertib significantly 
increased pAkt vs control and a significantly decreased of pS6 vs control (Figure 4-1). The PI3K 
inhibitor LY294002 worked as expected by inhibiting pAkt 79% and its downstream target pS6 
89% (Figure 4-1). Ipatasertib also worked as expected by increasing pAkt 26% over control 
while inhibiting pS6 40% (Figure 4-1). Interestingly, adding LY294002 first prevented the 
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increased of pAkt by Ipatasertib. These results were consistent with previous findings (Kui et al. 
2012). 
Next, we assessed the effect on viability, proliferation, invasion, and colony formation in 
MDA-MB-231 TNBC cells. Ipatasertib reduced viability in a concentration dependent manner 
from 1  𝜇M (62% viable) to 300  𝜇M (4.5% viable) with an IC50 value of 10.4  𝜇M (Figure 4-2 A). 
Equal ratios (1:1) of Ipatasertib to XMD8-92 reduced viability in a concentration-dependent 
manner (Figure 4-2 B). In Wright et al. 2018 the 1:1 combinations were determined to be 
synergistic (CI<1). Additionally, staggered ratios of  1:3 of Ipatasertib to XMD8-92  exhibited 
the strongest synergy with CIs of 0.11 and 0.25, respectively (figure 4-2 C). Conversely 3:1 
ratios of Ipatasertib to XMD8-92 resulted in antagonism with CIs of 1.24 and 1.09, respectively 
(Figure 4-2 C). Additional analysis of the 1:3 Ipat:XMD combo revealed the sparing of ERK1/2 
kinase activity and low toxicity in MCF10A cells (Wright et al. 2018). The MCF-10A cell line 
was selected as a normal tissue control because it is considered to be basal B but it does not 
contain driver mutations such as BRAF, KRas, or TP53 (MDA-MB-231 is also basal B; Kao et 
al. 2004).   
The Ipatasertib plus XMD8-92 combination also decreased proliferation in MDA-MB-
231 cells (Figure 4-3). This was evidenced by the decrease in Ki67 expression in both the 
XMD8-92 and combination groups. These results were similar to other reports of p21 induced 
cell cycle arrest in TP53 mutant TNBC cells (He et al. 2019). The morphology of the cells in the 
combination group appeared mesenchymal and ERK1/2 activity was spared; which prompted 
concerns of cell invasion (Liu Y et al. 2015). Therefore, we examined invasion in a basement 
membrane trans-well assay. Each drug alone decreased invasion by 58% (Ipatasertib) and 48% 
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(XMD8-92) (Figure 4-4 A). The combination decreased invasion by 50% and was not 
significantly different from the drugs alone.  
As mentioned in chapter 3, MDA-MB-231 cells are resistant to MEK inhibition in 2 D 
culture but are sensitive in 3 D culture (Li Q et al. 2010).  Therefore, we determined to effect of 
dual Akt and ERK5 inhibition on colony formation in a 3 D culture system. MDA-MB-231 cells 
were grown in soft agar for 7 days and treated with Ipatasertib and XMD8-92 alone or in 
combination. Ipatasertib did not decrease colony formation 103% vs control while XMD8-92 did 
significantly decrease colony formation alone (44%) and in combination with Ipatasertib (73%) 
(Figure 4-4 B). The latter was significantly different than both drugs alone.  
  
 
Figure 4-1 Evaluation of clinical Akt inhibitor Ipatasertib in MDA-MB-231 cells. MDA-
MB-231 cells were treated with 1  𝜇M Ipatasertib and LY294002 for 1 hour prior to 50ng/mL 
EGF stimulation for 15 minutes. DMSO was used as a vehicle control. Western blot analysis was 
performed on cellular lysates. Phosphorylated Akt (Serine 473) (A) and Phosphorylated S6 
(Serine 240/244) (B) levels were quantified using image studio lite. *P<0.05, **P<0.01, 





Figure 4-2. Ipatasertib combined with XMD8-92 synergistically reduces viability in MDA-
MB-231 cells. MDA-MB-231 cells were treated with Ipatasertib alone (A) or in 1:1 (B) and 1:3 
or 3:1 (C) combinations with XMD8-92 for 72 hours. Cell viability was determined using the 













Figure 4-3. Ipatasertib combined with XMD8-92 decreases proliferation marker Ki67 in 
MDA-MB-231 cells. MDA-MB-231 cells were treated with Ipatasertib and XMD8-92 alone or 
in combination for 72 hours under 5% FBS stimulation. DMSO was used as a vehicle control. 
Cells were fixed and probed with fluorescent antibodies for Tubulin and Ki67 and imaged with 
an EVOS-fl inverted microscope under 20x magnification. The ratio of Ki67 to Hoechst positive 





Figure 4-4. Ipatasertib plus XMD8-92 decreases colony formation and invasion in  MDA-
MB-231 cells. MDA-MB-231 were seeded in the top chamber of a matrigel transwell system and 
were allowed 24 hours to invade to the bottom chamber containing 10% FBS (A). Invasive cells 
were analyzed fluorescently as per the kit instructions. *P<0.01 vs FBS control. MDA-MB-231 
cells were grown in soft agar and treated with Ipat and XMD alone or in combination for 7 days 
(B). Colony formation was determined as per the kit instructions. **P<0.01 and ****P<0.0001 









4.3.2 Ipatasertib in MDA-MB-231 ERK5 KO 
 
Next, we sought to elucidate the mechanism of synergy the Ipatasertib plus XMD8-92 
combination. Since the molecular tools for investigating ERK5 are limited, we used MDA-MB-
231 ERK5 KO cells obtained from Matthew Burow’s Lab at Tulane University, New Orleans. 
The ERK5 KO cells were first characterized for ERK5 expression (Figure 4-5A). The MDA-
MB-231 ERK5 KO cells were then treated with increasing concentrations of the Akt inhibitor 
Ipatasertib. In particular, 100 nM Ipatasertib significantly decreased viability by 28% (compared 
to vehicle control) in the ERK5 KO cell line compared to 12% (compared to vehicle control) for 
the same concentration in the wild type cell line (Figure 4-5B). Additionally, a modest difference 
in IC50 was observed between the wild type (10.4  𝜇M) and ERK5 KO (6.6  𝜇M) cell lines. These 
results were less encouraging than the Ipatasetib plus XMD8-92 combination (Chapter 4). 
Therefore, we investigated an off target effect of XMD8-92: BRD4 inhibition (Lin EC et al. 
2016). BRD4 a member of the bromodomain and extra terminal domain family (BET) and is an 
epigenetic regulator involved in expression of the oncogene cMYC in several cancers (Da Costa 
et al. 2013). The BRD4 inhibitor CPI203 (Wong et al. 2014) was selected and administered in 
combination with Ipatasertib in the MDA-MB-231 ERK5 KO cells. Both CPI and Ipatasertib 
alone decreased viability 28% (compared to vehicle control) at a concentration of 100 nM in the 
ERK5 KO cell line (Figure 4-6A). The 1:1 combination of Ipatasertib to CPI (100 nM each) 
decreased MDA-MB-231 ERK5 KO cell viability by 63% (compared to vehicle control) and was 
significantly different than either drug alone (Figure 4-6A). Additionally, the 1:1 combination 
results approximately recapitulated the Ipat+XMD combo from Figure 4-2B. 
With BRD4 looking like a major factor in the proliferative component, we sought to 
explore the role of ERK5 in apoptosis. Previous studies have shown that ERK5 regulates the 
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proapoptotic protein Bad through phosphorylation of serine 112 (Pi et al. 2004, Wright et al. 
2019). The regulation of Bad by ERK5 was shown to be independent of ERK1/2 and p90RSK. 
To address this we performed an ELISA for pBad S112 in MDA-MB-231 WT and MDA-MB-
231 ERK5 KO cell types (Figure 4-7). Interestingly, the pBad 112 activity was abolished in the 
231 ERK5 KO cell line since the cells were not responsive to EGF (Figure 4-7A). To ensure this 
result was not due to assay error, control proteins for Bad and pBad were incubated with spare 
wells from the ELISA plate. The results indicated that the kit was working properly (Figure 4-
7C). We considered the possibility that the pBad s112 is transiently inhibited or activated by 
EGF. MDA-MB-231 WT and MDA-MB-231 ERK5 KO cells were then treated with EGF for 15 
minutes, 1 hour 4 hours and 24 hours. In the MDA-MB-231 WT cell line pBad S112 
phosphorylation was sustained for 24 hours while the MDA-MB-231 ERK5 KO cell line did not 
show pBad S112 levels above basal activation (Figure 4-8A). Next, we considered that the pBad 
S112 downregulation in MDA-MB-231 ERK5 KO cells could be due to downregulation of 
ERK1/2 and p90RSK. However, pERK1/2 and p90RSK levels were not decreased by Ipatasertib 
or CPI-203 treatment across all time points tested (Figure 4-8C). Therefore, the phosphorylation 







Figure 4-5. ERK5 KO in MDA-MB-231 cells modestly enhanced sensitivity to Ipatasertib. 
ERK5 levels were determined via western blot analysis (A). 231 WT and 231 ERK5 KO cells 
were treated with various concentrations of Ipatasertib for 72 hours under 5% FBS stimulation 
(B). Cell viability was determined using the MTT assay. IC50 values were obtained using 







Figure 4-6. BRD4 inhibition enhances the effect of Ipatasertib in MDA-MB-231 ERK5 KO 
cells. MDA-MB-231 ERK5 KO cells were treated with Ipatasertib alone or in combination with 
BRD4 inhibitor CPI203 for 72 hours under 5% FBS stimulation (A). Cell viability was 
determined using the MTT assay. Cells were fixed and probed with fluorescent antibodies for 
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Tubulin and Ki67 (B). The ratio of Ki67 (D) to Hoechst (C) positive cells was used to determine 
the proliferative fraction. *P<0.05 vs drugs alone.  
 
 
Figure 4-7. ERK5 KO abolishes pBad 112 in EGF stimulated MDA-MB-231 cells. MDA-
MB-231 ERK5 KO cells were treated with Ipatasertib and CPI203 alone or in combination for 1 
hour prior to 50ng/mL EGF stimulation for 4 hours (A). pBad s112 levels were determined via 
ELISA. Basal and stimulated pBad 112 levels were compared between 231 WT and 231 ERK5 
KO (B). ELISA sensitivity for controls: Bad, pBad 112 and secondary antibody (C). P<0.001 vs 






Figure 4-8. pBad 112 decrease in 231 ERK5 KO cells was independent of pERK1/2 and 
p90RSK signaling. MDA-MB-231 ERK5 KO cells were treated with Ipatasertib and CPI203 for 
1 hour prior to 50ng/mL EGF stimulation for 15 min, 1hr, 4hr, and 24hr. Cellular lysates were 
analyzed with western blot analysis. Protein levels were obtained for pBad S112 (A and B), 
pERK1/2 (C), p90RSK (D), and GAPDH was used as a  





Figure 4-9. Synergy summary. 
Proposed synergy mechanism in MDA-MB-231 TNBC cells. Ipatasertib and XMD8-92 
treatment decrease the phosphorylation of Bad at two separate sites which induces apoptosis. 
Additionally, XMD8-92 inhibits BRD4, which leads to p21 expression and a decrease in 
proliferation.  
 
4.3.3 ERK5 KO enhances conventional therapy Paclitaxel in MDA-MB-231 cells 
 
To tie together the relevance of ERK5 KO in MDA-MB-231 cells, we examined the 
effect of adding conventional chemotherapy Paclitaxel. Significant differences in viability 
between MDA-MB-231 WT and MDA-MB-231 ERK5 KO were observed beginning at 1 nM 
and continuing to 10 nM (Figure 4-10). The IC50s between the two cell lines were also 
significantly different by approximately 7 fold; 5.9 nM for MDA-MB-231 WT and 0.89 nM for 
MDA-MB-231 ERK5 KO (Figure 4-10). These results are similar to previous results that showed 
ERK5 knockdown, with shRNA, enhanced microtubule inhibitor efficacy in breast cancer cell 

















Figure 4-10. ERK5 KO enhances sensitivity to conventional therapy Paclitaxel in MDA-
MB-231 TNBC cells. MDA-MB-231 WT and ERK5 KO cells were treated with Paclitaxel for 
72 hours under 5% FBS stimulation. Cell viability was determined using the MTT assay. 
*P<0.05 vs 231 WT cell line. IC50 values were determined with Microsoft excel. 
 
4.4 Discussion  
 
Figure 4-2 demonstrates the synergy of Ipatasertib plus XMD8-92. 1:1 and 1:3 ratios achived 
CIs below one (synergistic). Whereas, 3:1 combinations of Ipatasertib to XMD8-92 were 
antagonistic (CI>1). These results were similar to previous studies, which examined 
combinations of Akt and MEK1/2 inhibitors and observed synergy at 1:2, 1:4, and 1:8 ratios and 
antagonism with 4:1 and 8:1 ratios in lung cancer cell lines (Meng et al. 2010). However, in our 
study we were able to achieve synergy while sparing ERK1/2 activity, thus indicating a distinct 
inhibitory pattern. Another distinction is our study is the type of synergy. Synergy obtained from 
dual PI3K and MEK1/2 is considered to be parallel. While synergy obtained from BRAF and 
MEK1/2 is considered to be serial (Yin et al. 2014). We propose the synergy between Akt and 
ERK5 to be serial rather than parallel due to the feedback loop between the two (Chapter 3) and 
the modifications of anti-apoptotic protein such as Bad (Figure 4-9). However, these aspects 
primarily describe synergy with respect to viability. Therefore the question becomes: Is 
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Ipatasertib+XMD8-92 synergistic with respect to invasion, proliferation, and colony formation? 
The answer is more complicated due to the involvement of BRD4. 
According to our earlier work, Wright et al. 2018, inhibition BRD4 in MDA-MB-231 cells 
does play an important role in the antiproliferative effect of Ipat+XMD by reducing Ki67 
expression and inducing p21 expression. This was shown in the IF images in Figure 4-3. Due to 
the mesenchymal morphology observed in Figure 4-3 we were concerned with invasion in the 
combination group. In our study, we did not observe increased invasion (Figure 4-4A). 
Additionally, the mesenchymal shape of the cell may be explained by the inhibition of BRD4 
which promotes that shape but is not necessarily more invasive (Andrieu and Denis 2018). 
Another contribution to the cell shape could be the prolonged expression of p21. In Wright et al. 
2018, p21 expression was significantly increased at 24 hours in groups containing XMD8-92 or 
the BRD4 inhibitor CPI-203. Prolonged p21 expression has been associated with senescence in 
TP53 mutant tumors and not necessarily an invasive phonotype (Chang et al. 1999). However, 
new concern arises if the cells are dormant and still have the ability to form tumors. Therefore, 
we examined the effect of dual inhibition on colony formation. In the 7 day period the 
combination was much more effective than either drug alone (Figure 4-4B). These results are in 
line with previous work that has shown ERK5 knock down disrupts colony-stimulating factor 
signaling (Dong et al. 2001; Rovida et al. 2008). Taken together, BRD4 appear to contribute to 
the anti-proliferative effects of Ipatasertib+XMD8-92 while ERK5 is involved in colony 
formation.  
To further elucidate the synergy mechanism we utilized the MDA-MD-231 ERK5 KO cell 
line. Knocking out ERK5 only had a modest effect on cell viability when treated with Ipatasertib 
and shifted the IC50 from 10.4 𝜇M (231 WT) to 6.6 𝜇M with (231 ERK5 KO) (Figure 4-5B). 
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Addition of the BRD4 inhibitor CPI203 in the MDA-MB-231 ERK5 KO reduced cell viability to 
similar levels seen with the Ipatasertib+XMD combination in 231 WT cells (Figure 4-2B and 
Figure 4-6B). Next, we sought to examine the effect of ERK5 KO in the pro-apoptotic protein, 
Bad. Interestingly, the phosphorylation of pBad S112 was decreased to near basal levels and was 
not responsive to EGF even at multiple time points (Figure 4-7A and Figure 4-8B). Furthermore, 
the decrease in pBad S112 did not correspond to a decrease in ERK1/2 and p90RSK (Known to 
phosphorylate pBad S112). BIM is a BH3 protein that promotes cell death is response to cellular 
stress (Bouillet et al. 1999). The role combined with paclitaxel is more complicated since 
paclitaxel effects the mitotic phosphorylation of BIMEL via CDK1 phosphorylation, which leads 
to polyub of BIMEL and degradation via the proteasome. In this case, in HCT116 cells was 
independent of ERK1/2 and ERK5 (Gilley et al. 2012). Therefore, it is possible that the decrease 
in pBad S112 is due to CDK1 downregulation due to the ERK5 KO. Further studies are needed 























Chapter 5: Evaluation of Ipatasertib plus XMD8-92 in PTEN altered TNBC 
 
5.1 Introduction  
 
 PTEN is a tumor suppressor gene that is frequently altered in TNBC (Chavez et al. 2010). 
Loss of PTEN enhances cancer cell survival and proliferation via the PI3K/Akt/mTOR signaling 
axis. Various mechanisms contribute to PTEN alteration: loss of function point mutations, hetero 
or homozygous deletion on chromosome 10, suppression via miRNA, degradation due to stress, 
and epigenetic suppression (Laugher et al. 2001, Li N et al. 2017, Shao et al. 2017). PTEN is 
altered in approximately 35% of TNBCs and less frequently in HER2+ (10%) and luminal A/B 
(5%) IDCs (The cancer genome atlas 2012). PTEN loss in TNBCs occurs primarily due to 
homozygous deletion while HER2+ breast cancers lose PTEN in response to Trastuzumab 
treatment (Li N et al. 2017). Clinically, PTEN and PI3K mutation status correlate with 
Trastuzumab resistance and decreased response rates in patients with HER2+ breast cancer 
(Rimawi et al. 2018). Mechanistically, when PTEN is downregulated HIF-1a remains stable in 
the hypoxic conditions generated by Trastuzumab treatment (Aghazadeh et al. 2017).  The 
stabilization of HIF-1a facilitates the expression of genes such as VEGF, a prompter of 
angiogenesis (Laugher et al. 2001). In summary, PTEN status is widely considered an 
“actionable” alteration due to its potential for targeted therapy at both the pre-clinical and clinical 
levels.  
In our initial studies, MDA-MB-231 (TNBC; PTEN WT) cells treated with XMD8-92 
exhibited increased levels of pAkt (S473). Groups treated with both Ipatasertib and XMD8-92 
appeared to “capture” more pAkt (S473) than either drug alone (Wright et al. 2018). These 
results were remarkable since Ipatasertib is generally considered non-effective in PTEN WT 
cancer cell lines (Lin J et al. 2013). Therefore, we propose that XMD8-92 sensitizes the PTEN 
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WT MDA-MB-231 cells by modulating PTEN expression. We will evaluate the enhancement of 
Ipatasertib by XMD8-92 in two PTEN mutant TNBCs: BT549 (Basal B) and MDA-MB-468 
(Basal A) cells.   
5.2 Hypothesis  
 
Ipatasertib plus XMD8-92 will decrease viability in PTEN mutant or PTEN inhibited TNBC cell 
lines: MDA-MB-468 (mut), BT549 (mut), and MDA-MB-231 (PTENi).  
5.3 Cellular models  
 
MDA-MB-468 cells are derived from pleural effusions and are adenocarcinomas in 
origin. MDA-MB-468 cells are Basal A and grow in “grape-like” clusters in 2D cell culture and 
have round morphology (Kenny et al. 2007). MDA-MB-468 cells harbor TP53 and PTEN driver 
mutations (Hollestelle et al. 2009). Additionally, MDA-MB-468 cells have a rare amplification 
of EGFR (1-6% occurrence, Filmus et al. 1985, Bhargava et al. 2005). MDA-MB-231 cells are 
also derived from pleural effusions and are adenocarcinomas in origin. MDA-MB-231 cells are 
Basal B and grow in stellate patterns in 2D cell culture (Neve et al. 2006, Kenny et al. 2007, Kao 
et al. 2009). MDA-MB-231 cells are PTEN wild type and harbor TP53 and KRAS driver 
mutations (Hollestelle et al. 2009). BT-549 cells are derived from primary tumors and are 
invasive ductal carcinomas (IDCs). BT-549 cells are Basal B and grow in stellate patterns in 2D 
culture and have similar morphology as MDA-MB-231 cells (Neve et al. 2006, Kenny et al. 
2007, Kao et al. 2009). BT-549 cells harbor TP53 and PTEN driver mutations (Hollestelle et al. 
2009). Lastly, MCF10A cells were used as a normal tissue control. MCF-10A cells are derived 
from normal breast tissue and are Basal B subtype (Neve et al. 2006, Kao et al. 2009). This cell 
line does not harbor any driver mutations as seen in the other TNBC cell lines and therefore is 
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considered “normal”. However, MCF-10A cells can be progressively transformed by KRas and 
HRas mutations (Santner et al. 2001).  
5.4 Results 
 
5.4.1 PTEN degradation in MDA-MB-231 TNBC cells 
 
The Ipat+XMD combination in MDA-MB-231 (Basal B) cells exhibited increased pAkt 
and decreased PTEN levels (Wight et al. 2019; Figure 5-1A and B). Additionally, HIF-1a 
expression was significantly increased in the Ipat+XMD combination group. These data are 
consistent with previous work that showed HIF-1a stabilization with concurrent PTEN 
downregulation (Laughner E et al. 2001, Safyeh Aghazadeh et al. 2017, Azimi et al. 2017). We 
observed similar results in the MCF-10A (Basal B) cell line (Figure 5-2). The decrease in PTEN 
and increase in pAkt was only seen at the 1,3 uM concentration in the MCF-10A cell line (Figure 
5-2B). At the 1,3 uM concentration viability was modestly reduced by 22% in the MCF-10A 
cells (Figure 5-2A). These results were line with Lin J et al. 2013 who showed PTEN KO in 
MCF-10A cells sensitized Ipatasertib treatment. Next, we attempted to establish if PTEN 
inhibition was the primary source of Ipatasertib efficacy in a PTEN WT TNBC cell line. We 
treated MDA-MB-231 with a PTEN inhibitor (PTENi) and added Ipatasertib in combination. 
The PTEN inhibitor alone increased both pAkt and pS6 1.5 and 1.3 fold over control, 
respectively (Figure 5-3 B and C). Ipatasertib behaved as expected and increased pAkt 1.8 fold 
over control while reducing pS6 activity by 60% with respect to control. Lastly, the combination 
of PTENi and Ipatasertib increased pAkt 2.2 fold and decreased pS6 activity by 75% (Figure 5-3 
B and C). Although the principle of the assay was a success, the PTENi+Ipat combination did 
not affect viability more than Ipatasertib alone (Figure 5-3A). The inhibition of PTEN did not 
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enhance the effect of Ipatasertib. Therefore, PTEN status in the MDA-MB-231 cell line was not 




Figure 5-1. Ipat+XMD condition induces PTEN degradation in MDA-MB-231 TNBC cells. 
MDA-MB-231 cells were treated with Ipatasertib and XMD8-92 alone or in combination for 24 
hours under 25ng/mL EGF stimulation or 5% FBS for 24 hours. Cellular lysates were analyzed 
with ELISA (left) and western blot (right). MDA-MB-468 (PTEN null) lysates were used for the 
PTEN ELISA and GAPDH was used as a loading control for the western blot (A and B). 








Figure 5-2. Ipat+XMD decreases PTEN expression and increases pAkt in MCF10A cells. 
MCF10A cell lines were treated with Ipat+XMD at various concentrations for 72 hours under 
20ng/mL EGF stimulation (A). Cells were visualized with an EVOSfl inverted microscope under 
a 10x objective. Cell lysates were obtained for Ipat and XMD treated cells for 24 hours under 







Figure 5-3. Ipatasertib efficacy is not enhanced by inhibited PTEN in MDA-MB-231 cells. 
MDA-MB-231 cells were treated with PTENi and Ipatasertib alone or in combination for 72 
hours under 5% FBS stimulation (A) In the combination group 100 nM PTENi was used. 
*P<0.05 vs PTENi alone. Cellular lysates were collected and analyzed with western blot (B and 
C). Levels of pAkt (S473) and pS6 (S240/244) were determined. *P<0.05, **P<0.01 vs 
DMSO+FBS control, # vs Ipat and PTENi alone.  
 
5.4.2 Effect of Ipatasertib plus XMD8-92 in Basal B (mesenchymal) PTEN mutant BT-549 
cell line 
 
The BT549 cell line was selected because it is a basal B TNBC (similar to MDA-MB-
231). However, the BT549 cell line harbors a PTEN mutation, whereas the MDA-MB-231 cell 
line does not.    
Both Ipatasertib and XMD8-92 alone reduced viability in a concentration dependent 
manner. Ipatasertib was more potent with an IC50 of 8.1 𝜇M while XMD8-92 had an IC50 of 44 
𝜇M (Figure 5-4A). In 1:1 combinations, concentrations 3,3 and 10,10 𝜇M decreased viability 
significantly more than each drug alone (Figure 5-4A). The combinations were also synergistic 
with CIs of 0.44 and 0.28, respectively. Combinations of 1:5 also achieved synergy while 
maintaining minimal collateral toxicity with respect to MCF-10A cells (Figure 5-4B). In 
particular the 1,5 𝜇M combination decreased viability by 70% in BT-549 cells vs 30% in the 
MCF-10A cells. Additionally, the 1,5  𝜇M combination was synergistic with a CI of 0.23. Lastly, 
the 1:5 combinations did not enhance the effect of 100 pM Paclitaxel in BT-549 cells (Figure 5-
4C). Each drug alone was similar to the control’s proliferative index however; the combination 
did decrease the Ki67/Hoechst ratio. Ki67/Hoechst Control (60%) Ipat (58%) XMD (52%) and 
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I+XMD (39%). Both XMD alone or in combination increased expression of the cell cycle 
inhibitor p21 by 1.5 and 2.1 fold, respectively (Figure 5-5). Taken together, these data suggest 
the combination of Ipatasertib and XMD8-92 decreases proliferation in BT549 cells. 
Both Ipatasertib and XMD8-92 contributed to the decrease in pBad S112: Ipat (77% of 
control) XMD (67% of control) I+XMD (54% of control) (Figure 5-6A). Additionally, the 
decrease in pBad S112 corresponded to an increase in cleaved caspase-3: 4.9 fold vs control for 
Ipatasertib and 7.3 fold vs control for the combination (Figure 5-6B). These results were similar 
to what was previously observed in the MDA-MB-231 cell line (also a Basal B TNBC cell type). 
Genetic ablation of ERK5 in BT-549 cell was attempted by Dr. Matthew Burow’s lab but was 
unsuccessful. Therefore, ERK5 appears to be critical for BT-549 cell survival.  
Concerning kinase activity, XMD8-92 worked as expected and decreased the 
phosphorylated levels of ERK5 alone 38% and 64% in combination (Figure 5-7A). Interestingly, 
Ipatasertib also decreased pERK5 although the response was not statistically significant 
(P<0.0502). However, it is possible that Ipatasertib’s effect on ERK5 in BT549 cells is 
biologically significant. For example, pBad S112 decreased in the presence of Ipatasertib alone, 
and this could be indirect due to its inhibition of ERK5 (Figure 5-6A). Also, the combination of 
Ipatasertib and XMD8-92 inhibited pERK5 apparently more than either inhibitor alone (again 
not significant; P<0.085 but could be biologically relevant). Across all treatment groups, 
pERK1/2 signaling was not affected (Figure 5-7B). As expected, pAkt levels were increased in 
the presence of Ipatasertib alone or in combination 2 fold and 2.8 fold over control, respectively 
(Figure 5-7C). Downstream of Akt, pS6 levels were decreased by 80% in presence of Ipatasertib 






Figure 5-4. 1:5 ratios of Ipat:XMD were effective in BT-549 TNBCs while exhibiting 
minimal collateral toxicity in MCF-10A cells. BT-549 TNBC cells were treated with 
Ipatasterib and XMD8-92 at 1:1 and 1:5 ratios for 72 hours under 5% FBS stimulation (A and 
B). *P<0.05 vs drugs alone. Additionally, MCF-10 cells were treated with 1:5 combinations for 
72 hours under manfg instructions (B). *P<0.05 vs MFC10. Lastly, BT-549 cells were treated 
with 100pM Paclitaxel for 24 hours followed by Ipat+XMD for 48 hours (C). Cell viability was 











Figure 5-5. Ipat+XMD decreases proliferation marker Ki67 and induces p21 expression in 
BT-549 cells. 
BT-549 cells were treated with Ipatasertib and XMD8-92 for 24 or 72 hours under 5% FBS 
stimulation. Cells were analyzed via immunofluorescence for Ki67 (A). Western blot was 
performed on cellular lysates after 24 hours of treatment and p21 levels were obtained (B). Cell 
counts were obtained by counting Hoechst positive cells (C) and proliferative cells were 






Figure 5-6. Both Ipatasertib and XMD8-92 decreased pBad S112 while Ipat increased 
Cleaved caspase-3 in BT-549 cells. BT549 cells were treated with Ipatasertib and XMD8-92 for 
1 hour prior to 50ng/mL EGF for 4 hours. Cellular lysates were analyzed with an ELISA for 
pBad S112 (A). *P<0.05 and **P<0.01 vs EGF control.  BT549 cells were treated for 48 hours 
followed by analysis via ELISA for Cleaved Caspase-3 (B). ***P<0.001 and ****P<0.0001 vs 
control. ##P<0.01 vs both drugs alone.  
 
 
Figure 5-7. Ipatasertib plus XMD8-92 combination inhibits respective kinases while 
sparing ERK1/2 activity in BT549 cells. BT549 cells were treated with Ipatasertib and XMD8-
92 alone or in combination for 1 hour prior to treatment with 5% FBS for 24 hours. Cellular 
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lysates were analyzed with western blot and levels of pERK5 (A), pERK1/2 (B), pAkt (C), and 
pS6 (D) were obtained. GAPDH was used as a loading control. *P<0.05, and **P<0.01 vs 
control. Representative western blot (E). 
 
5.4.3 Effect of Ipatasertib plus XMD8-92 in Basal A (basal) PTEN mutant MDA-MB-468 
cell line 
 
MDA-MB-468 cells are basal A and harbor a homozygous PTEN deletion (Hollestelle et 
al. 2009). When treated with Ipatasertib alone, cell viability was decreased in a concentration 
dependent manner with an IC50 of 5.4 𝜇M (Figure 5-8A). XMD8-92 on the other hand, was not 
able to reduce viability enough to determine an IC50 value. Therefore combination index (CI) 
values for synergy were not calculated. We decided to use 1:5 ratios of XMD8-92 due to the 
success in the BT-549 (Figure 5-4 B) cell line and previous reports of ERK1/2 activity spared at 
5 𝜇M XMD8-92 (Yang et al. 2010). There were no significant differences in viability until the 
1,5 𝜇M combination: 40% viable in MDA-MB-468 and 71% viable in MCF10A (Figure 5-8B). 
With respect to proliferation, only the combination group reduced Ki67/Hoechst ratio compared 
to control (Figure 5-9A). Morphologically, the combination appeared to disrupt the “grape- like” 
cluster of MDA-MB-468 cells (Figure 5-9A). Additionally, the 1:5 combination appeared to 
increase p21 expression 1.8 fold over control however; this was not statistically significant 
(P<0.07) (Figure 5-9B). Ipatasertib decreased pBad S112 both alone 37% and in combination 
with XMD8-92 41% vs control (Figure 5-10A). XMD8-92 only modestly decreased pBad S112 
by 16% however, this was not significant vs control. Surprisingly, Cleaved caspase-3 levels were 
not elevated above control in any of the treatment groups (Figure 5-10B); which was counter 
what was observed in MDA-MB-231 and BT-549 cells. Interestingly, Ipatasertib decreased 
pERK5 levels alone 64% and in combination 85% vs control (Figure 5-11A). XMD8-92 
increased pAkt levels 3.7 fold over control (Figure 5-11C). Lastly, pERK1/2 levels were 
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significantly increased in the XMD8-92 alone (2 fold over control) and combination groups (1.5 





Figure 5-8. Ipatasertib potentiates XMD8-92 in 1:5 ratio in Basal A TNBC MDA-MB-468 
cells. MDA-MB-468 cells were treated with Ipatasterib and XMD8-92 at 1:1 and 1:5 ratios for 
72 hours under 5% FBS stimulation (A and B). Additionally, MCF-10 cells were treated with 1:5 
combinations for 72 hours under 20ng/mL EGF stimulation (B). *P<0.05 vs MFC10. Lastly, 
BT549 cells were treated with 100pM Paclitaxel for 24 hours followed by Ipat+XMD for 48 












Figure 5-9. Ipatasertib plus XMD8-92 decreases Ki67 expression in MDA-MB-468 cells. 
MDA-MB-468 cells were treated with Ipatasertib and XMD8-92 for 24 or 72 hours under 5% 
FBS stimulation. Cells were analyzed via immunofluorescence for ki67 (A). Western blot was 
performed on cellular lysates from 24 hours of treatment and p21 levels were obtained (B). Cell 
counts were obtained by counting Hoechst positive cells (C) and proliferative cells were 






Figure 5-10. Ipatasertib decreases pBad s112 but fails to induce apoptosis in MDA-MB-468 
cells. MDA-MB-468 cells were treated with Ipatasertib and XMD8-92 for 1 hour prior to 
50ng/mL EGF for 4 hours. Cellular lysates were analyzed with an ELISA for pBad S112 (A). 
MDA-MB-468 cells were treated for 48 hours followed by analysis via ELISA for Cleaved 








Figure 5-11. Ipatasertib decreased pERK5 while XMD8-92 increased pERK1/2 in MDA-
MB-468. MDA-MB-468 cells were treated with Ipatasertib and XMD8-92 alone or in 
combination for 1 hour prior to treatment with 5% FBS for 24 hours. Cellular lysates were 
analyzed with western blot and levels of pERK5 (A), pERK1/2 (B), and pAkt (C) were obtained. 
GAPDH was used as a loading control. *P<0.05, and **P<0.01 vs control. Representative 


















5.5 Discussion  
 
PTEN is mutated in approximately 30% of all cancers and is frequently altered in TNBC 
(Chavez et al. 2010, Bailey et al. 2018). PTEN is extensively studied as an oncogenic driver and 
therapies targeting PI3K/Akt/mTOR are implemented with the aim of precision oncology 
treatment. For example, Ipatasertib is primarily indicated for locally advanced TNBC patents 
with PTEN alterations (Phase III trial; NCT03337724). Targeted agents are also investigated in 
patents with treatment-induced loss of PTEN. The PI3K𝛼 inhibitor Alpelisib (BYL719) worked 
syngersitically with lapatinib in HER2+ PTEN deficient breast cancer tumors in vivo (Zhang et 
al. 2016). Alpelisib is currently in phase II clinical trials for Her2+ breast cancer and metastatic 
breast cancer (MBC) (NCT03706573). Although PTEN status is an important pre-clinical and 
clinical benchmark, our study demonstrates the variability of treatment response across three 
different TNBCs.  
In our preliminary studies (Chapter 3) we observed elevated levels in pAkt in the 
presence of XMD8-92. This led us to examine the PTEN status in the PTEN WT MDA-MB-231 
cell line. Interestingly, XMD8-92 treatment decreased PTEN levels and increased HIF-1a levels 
in MDA-MB-231 cells (Figure 5-1). These results are similar to previous studies that observed 
PTEN degradation under stress conditions (Laugher et al. 2001, Aghazadeh et al. 2017). One 
concern of the Ipat+XMD treatment is that it could sensitize PTEN WT tissues to Ipatasertib via 
PTEN degradation. To address this, we examined Ipat+XMD in the MCF-10A cell line (Basal 
B). PTEN levels were decreased in the MCF-10A cell line (Figure 5-2). However, the viability 
was only modestly reduced by 22% (Figure 5-2). One factor that may explain the preferential 
toxicity in TNBC vs MCF-10A is that MDA-MB-231 cells express pBad S112 at higher levels 
than MCF-10A (Stickles et al. 2015). 
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 Next, we mimicked the conditions induced by XMD8-92 by inhibiting PTEN in MDA-
MB-231 cells. Functionally, the assay performed as intended: pAkt was increased (Figure 5-3 B 
and C). However, the increased pAkt conditions alone were not enough to increase Ipatasertib 
efficacy in the viability assay (Figure 5-3 A). Therefore, ERK5 appears to play a crucial role in 
the synergy mechanism.  
Across all three TNBC cell lines the Ipatasertib plus XMD8-92 combination decreased 
viability via synergy (MDA-MB-231 and BT-549) or potentiation (MDA-MB-468). 
Additionally, the combination decreased the proliferation marker Ki67 expression in each cell 
type (Figure 5-5 and Figure 5-9). The mechanism of synergy was determined to be pBad 
inhibition followed by caspase activation in the MDA-MB-231 and BT-549 cell lines (Figure 4-7 
and Figure 5-6). The MDA-MB-468 cell line did not appear to activate caspases under the 
conditions tested (Figure 5-10). The performance of Ipat+XMD is summarized in table 5-1 
below. 
Cell line Cell type PTEN status Ipat+XMD Mechanism 
MDA-MB-231 Basal B WT Synergy Caspase activation 
BT549 Basal B Null Synergy Caspase activation 
MDA-MB-468 Basal A Null Potentiation Undetermined  
Table 5-1. Summary of Ipat+XMD combination in TNBC cell lines. 
 
The kinase activity, pBad signaling, and caspase activation in BT-549 cells were similar 
to the MDA-MB-231 cells (Chapter4). The MDA-MB-468 cells, on the other hand, behaved very 
differently. MDA-MB-468 cells treated with Ipat+XMD did not exhibit increased cleaved 
caspase activity. Perhaps this is due to the unique receptor expression profile of MDA-MB-468 
cells. MDA-MB-468 cells overexpress cMET. cMET is the receptor for HGF and is observed in 
many cancers. In addition to activating growth factor signaling, cMET contains a domain that 
inhibits caspases (Jung et al. 2012). The Ipat+XMD combination in MDA-MB-468 cells also 
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activated pERK1/2 signaling (Figure 5-11). This was in contrast with MDA-MB-231 and BT-
549 cell both of which pERK1/2 were spared. Another unique feature of MDA-MB-468 cells is 
that they have an EGFR amplification (Chavez et al. 2010). This may be what was responsible 
for the increased pERK1/2 activity in the XMD8-92 treated groups. Therefore, inhibiting EGFR 
may be needed to achieve full efficacy since ERK1/2 appears to be essential to survival in this 
cell line (She et al. 2005). Sohn et al. 2014, achieved synergy with EGFR and cMET inhibitor 
combinations in MDA-MB-468 cells. In their study, MDA-MB-468 cells had hyperactive pMET 
and pEGFR vs MDA-MB-231 cells. This led to increased downstream signaling in the presence 
of EGF in the MDA-MB-468 cells. Therefore, EGFR and cMET may need to be inhibited for 



























Chapter 6: Characterization of novel MEK5 and dual MEK5/Akt inhibitors in breast 
cancer cells 
 
6.1 Introduction  
 
Chapters 3, 4, and 5 all underscored the promise of ERK5 inhibition as a potential target 
for TNBC. Furthermore, ERK5 inhibition in combination with Akt inhibition was synergistic in 
TNBC and relatively non-toxic in a normal tissue control. However, the tools used to study 
MEK5/ERK5 signaling are limited and there is a need to develop novel, selective inhibitors of  
the MEK5/ERK5 pathway. Additionally, there are currently no known compounds that serve as a 
dual MEK5/ERK5 and PI3K/Akt inhibitor. Therefore, in this chapter, we will explore the 
synthesis of selective MEK5 and dual MEK5/Akt inhibitors in hopes of creating a targeted 
therapy for TNBC.  
Aberrations in the MAPK pathway have been extensively studied due to their role in 
tumor formation, metastasis, chemo-resistance, and angiogenesis. In particular, BRAF mutations, 
a kinase upstream of MEK, leads to hyperactivation of MEK1/2 and are considered driver 
mutations in various cancers (Bailey et al. 2018). Both BRAF and MEK1/2 have been 
successfully targeted in melanoma with FDA approved molecules Vorafinib and Trametinib 
respectively (Rheault et al. 2013, Salama and Kim 2013, Zhao and Adjei 2014). Additionally, 
Trametinib has recently been approved to treat V600E BRAF mutant lung cancer patients 
(Odogwu et al. 2018). As such, Trametinib serves as an example of successful precision 
oncology at the clinical level. 
MEK5/ERK5 is a less studied pathway compared to MEK1/2/ERK1/2. However, it has 
been identified as a key oncogenic signaling modulator in many cancer types (Hoang et al. 
2017). High MEK5 (50%) expression or ERK5 (20%) expression was observed in breast tumors 
and correlated with decreased disease free survival (Hsieh et al. 2005, Montero et al. 2009). 
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ERK5 has also been linked to breast tumor kinase (Brk), which is overexpressed in 86% of IDCs 
(Drew et al. 2012). In MCF-7 cells (ER+) ERK5 mediated chemoresistance, evasion of 
apoptosis, and enhanced survival (Weldon et al. 2002, Antoon et al. 2013). In BT474 cells (triple 
positive) ERK5 is constitutively active however introduction of a dominant negative form of 
ERK5 decreased proliferation (Esparis-Ogando et al. 2002). In MDA-MB-231 (TNBC) cells 
ERK5 mediated proliferation via CDK1 and p21 expression (Perez-Madrigal et al. 2012).   
Current strategies to target the MEK5/ERK5 have relied on a limited number of 
inhibitors. The ATP competitive inhibitors BIX02188 and BIX02189 were shown to have potent 
activity against MEK5 (in cell free assays) with IC50s of 4.3nM and 1.5nM, respectively. Neither 
displayed activity against MEK1/2 or EGFR, thus indicating selectivity for MEK5 over similar 
kinases (Tatake et al. 2008). BIX02189 treatment in colorectal cancer cells decreased 
proliferation, although only at high concentrations (Pereira DM, et al. 2016). XMD8-92 is an 
ATP competitive inhibitor of ERK5 with an IC50 (Kd) of 80nM (Yang et al. 2010). Inhibition of 
ERK5 with XMD8-92 decreased proliferation in HeLa cells by inducing p21 expression (Yang et 
al., 2010). XMD8-92 has also shown promise in prostate and pancreatic cancers. However, the 
effects of XMD8-92 have come under scrutiny since the molecule has been shown to inhibit 
BRD4 with moderate affinity (Li et al. 2016). Therefore, AX15836 was developed as a selective 
ERK5 inhibitor with and IC50 of 8 nM vs ERK5 and 3,600 nM vs BRD4 (Li et al. 2016).  
Our lab in collaboration with Dr. Patrick Flaherty, a medicinal chemist at Duquesne, 
began the search for new MEK5 inhibitors using benzimidazole based compounds. However, 
these compounds were unable to selectively inhibit MEK5/ERK5 activity in HEK293 cells 
(Flaherty et al. 2010). Therefore, our focus shifted towards type III non-ATP competitive 
allosteric inhibitors of MEK5. Advantages for type III inhibitors are that they do not have to 
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compete with ATP (milimolar concentrations in the cell) and are therefore potent (Ataullakanov 
and Vitvitsky 2002). MEK1/2 inhibitors PD0325901 (0.33 nM IC50 for MEK) and Trametinib 
(Table 7-1) were used as lead compounds (Barrett et al. 2008). Our recent work examined the 
structure activity relationship (SAR) of novel diphenylamine analogs as type III (allosteric) 
inhibitors of MEK5 (Chakrabarty et al. 2018). In this study, we screened novel diphenylamine 
and thiophene analogs for MEK5/ERK5, MEK1/2/ERK1/2, and Akt activity in the MDA-MB-
231 TNBC cell line. A detailed overview of the screening process is outlined in Figure 6-2. 
Additionally, results for the novel compound screen are tabulated in table 6-2. Selected 





Figure 6-1. Summary of MEK1/2 and MEK5 pathways and inhibitors in cancer. (Thomas 
Wright, Unpublished work). 
 
Compound Target(s) Type IC50 (nM) Reference 
BIX02188 MEK5 ATP-Competitive 4.5 Tatake, et al. 2008 
BIX02189 MEK5 ATP-Competitive 1.5 Tatake, et al. 2008 
XMD8-92 ERK5, 
BRD4 
ATP-Competitive 80, 190 Yang et al. 2010; Li et 
al. 2016 
AX15836 ERK5 ATP-Competitive 8 Li et al. 2016 
Trametinib MEK1/2 Type III-Allosteric 0.92, 1.8 Yamaguchi et al.2011 




Novel diphenylamine and thiophene derivatives will provide selective inhibition of MEK5 and 
MEK5+Akt respectively.  
 
 
Figure 6-2. Novel compound screening process. Kinase assay: MDA-MB-231 cells were 
treated with 10  𝜇M novel inhibitors for 1 hour prior to treatment with 50ng/mL EGF for 15 
minutes. Cellular lysates were collected and analyzed with western blot. Viability assay: MDA-
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MB-231 cells were treated with 10  𝜇M novel inhibitors for 72 hours under 5% FBS stimulation. 










AJM-1-12 SC-1-151+Linker 41.4 12.5 N/A 
AJM-1-18 
SC-1-151+Linker 
Salt 71 35.8 N/A 
AJM-1-19 SC-1-151+Biotin 65.9 22.9 N/A 
AJM-1-61 SC-1-151+DYE 22.3 79.4 N/A 
AJM-1-68 
SC-1-
151+BODIPY 70.1 75.5 N/A 
SC-1-151 Diphenylamine 0.5 59.4 135.6 
SC-1-181 Diphenylamine 108.5 17.6 85.4 
DS-1-95 
CYP Thiophene 91.9 81.2 N/A 
DS-1-95 
ISP Thiophene 85.8 62.5 N/A 
DS-1-118 Thiophene 74.3 54.3 N/A 
DS-4-13 Thiophene 95.7 97.4 N/A 
DS-4-15 Thiophene 110.1 103.5 N/A 
DS-4-23 Thiophene 95.4 101.8 N/A 
DS-4-89 Thiophene 96 89.4 N/A 
DS-4-125 Thiophene 83.9 101.2 N/A 
DS-4-149 Thiophene 104.1 51.9 N/A 
DS-4-160 Thiophene 67.6 127.1 N/A 
DS-4-162 Thiophene 113 30.9 N/A 
DS-4-187 Thiophene 94.4 107.2 N/A 
MG-2-72 Diphenylamine 91.4 63.7 N/A 
MG-2-77 Diphenylamine 128.9 168.4 N/A 
MG-2-82 Diphenylamine 98.7 116 N/A 
MG-2-83 Diphenylamine 129.9 49.1 N/A 




49.1 8.4 N/A 
MG-2-106 Diphenylamine 85.2 53.1 N/A 
MG-2-110 Indazole 68.3 113.5 N/A 
MG-2-111 Indazole 64.1 68.7 N/A 
MG-2-112 Quinazoline 35.4 39.7 N/A 
MG-2-117 Indazole 99.2 53.1 N/A 
MG-2-120 Indazole 53.7 38.8 N/A 
MG-2-125 Diphenylamine 154.5 72.8 N/A 
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MG-3-22 Thiophene 85.7 122.3 N/A 
MG-3-53 Thiophene 75.6 65.8 N/A 
MG-3-60 Thiophene 62.8 77 N/A 
MG-3-61 Thiophene 55.8 100.9 N/A 
MG-3-62 Thiophene 105.2 97.6 N/A 
MG-3-63 Thiophene 88.1 49 N/A 
MG-3-73 Thiophene 39 92.5 N/A 
MG-3-80 Thiophene 13.9 84.5 137.6 
MG-3-81 Thiophene 107.3 31.8 44.7 
MG-3-93 Thiophene 65.5 26.5 72.9 
MG-3-96 Thiophene 77.5 24.7 40.2 
MG-3-97 Thiophene 86 34.7 50.5 
MG-3-101 Thiophene 114 74.2 67.3 
MG-3-102 Thiophene 91 56.9 80.3 
MG-3-104 Thiophene 94.4 70.3 97 
MG-3-106 Thiophene 152 101.9 103.6 
MG-3-108 Thiophene 154 78.2 99.8 
MG-3-110 Thiophene 93.5 75.9 74.4 
MG-4-35 Diphenylamine 101.1 94.7 79.6 
MG-4-39 Diphenylamine 88.4 60.9 104.1 
MG-4-41 Diphenylamine 98.5 55.2 88.3 
MG-5-5 Thiophene 94.5 25.1 10.2 
MG-5-7 Thiophene 105.6 66.3 89 
Table 6-2. Summary of novel kinase inhibitor activity against ERK1/2, ERK5 and Akt. 
 
6.3 Results  
 
6.3.1 Dipehnyl amine analogs 
 
Novel diphenylamines described in Chakrabarty et al. 2018 were screened in the MTT 
viability assay. Only three compounds were able to achieve a significant reduction in viability: 
SC-1-151 (35%), SC-1-80 (20%), and SC-1-79 (20%) (Figure 6-3). SC-1-151 was further 
characterized due to its effects in the cellular viability assay and its EMT properties in MDA-
MB-231 TNBC cells (Hoang et al. 2016). In our study, SC-1-151 was determined to be a potent 
inhibitor of ERK1/2 phosphorylation with an IC50 value of 26 nM in MDA-MB-231 cells (Figure 
6-4). SC-1-151 was also shown to inhibit ERK5 phoshorylation by 40% at 10  𝜇M (Chakrabarty 
et al. 2018). Due to the interesting EMT properties of SC-1-151, we sought to determine the 
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cellular localization of SC-1-151. AJM-1-68 was synthesized: SC-1-151 with a BODIPY linked 
probe (Figure 6-5A). MDA-MB-231 cells were treated with AJM-1-68 imaged, and cellular 
lysates were collected. The AJM-1-68 compound appeared to enter the cell (Figure 6-5 B and C). 
AJM-1-68 remained significantly active in vitro at 1 𝜇M (30% ERK1/2 inhibition) (Figure 6-5 
D). The BODIPY dye alone did not affect ERK1/2 activity. Additional Immunofluorescence 
experiments are needed to precisely determine the localization of AJM-1-68 in vitro. Another 
interesting feature of SC-1-151 is that it increased pAkt in various experimental settings. This is 
consistent with previous reports of MEK inhibition induced Akt activation (Aksamitiene et al. 
2012). We then proposed SC-1-151 treatment followed by Ipatasertib would “capture” more Akt 
in the active conformation. Interestingly, increased pAkt was observed in SC-1-151+Ipatasertib 
in MDA-MB-231 and BT-549 TNBC cell lines (Figure 6-6). 
Next, we aimed to generate a novel selective inhibitor of MEK5. SC-1-181 was described 
in Chakrabarty et al. 2018 as the most selective diphenylamine MEK5 inhibitor to date: 82% 
ERK5 phosphorylation inhibited at 10  𝜇M. SC-1-181 was further characterized and exhibited an 
IC50 of 115nM vs pERK5 in MDA-MB-231 cells (Figure 6-7C). Additionally, SC-1-181 did not 
significantly inhibit ERK1/2, thus it was labeled as MEK5 selective (Figure 6-7B). Next, MDA-
MB-231 cells were treated with SC-1-181 for 72 hours. Cell viability decreased starting at 
30  𝜇M and leveled off at 300  𝜇M (Figure 6-8A). SC-1-181 was then tested in combination with 
Akt inhibitor Ipatasertib in 1:1 ratios. Significant reductions in viability were observed starting at 
1 𝜇M each and leveled off at 10  𝜇M each (Figure 6-8B). Staggered ratios were not examined 
since no IC50 with SC-1-181 was established. Furthermore, the SC-1-181 combination differed 
from the Ipat+XMD combination (Chapter 4) in that Akt was not activated. Lastly, we were able 
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to recapitulate the Ipat+XMD combo by using CPI. Ipat+XMD: 63% viability at 0.1,0.1 𝜇M 




Figure 6-3. Diphenylamine analog viability screen. MDA-MB-231 cells were treated with 
10  𝜇M novel inhibitors for 72 hours under 5% FBS stimulation. Cell viability was determined 
using the MTT assay. ****P<0.0.0001, **P<0.01, and *P<0.05 vs control.  
 
Figure 6-4. SC-1-151 potent novel inhibitor of MEK1/2. Structure of SC-1-151 (A). MDA-
MB-231 cells were treated with various concentrations of SC-1-151 for 1 hour prior to 50ng/mL 
EGF stimulation for 15 minutes. Western blot analysis of pERK1/2 inhibition by SC-1-151 (B). 










Figure 6-5. Cellular localization observed with Bodipy linked SC-1-151 (AJM-1-68) in 
MDA-MB-231 cells. MDA-MB-231 cells were treated with 10  𝜇M AJM-1-68 (A) for 6 hours 
prior to visualization with an EVOS-fl inverted microscope (B) 10x and (C) 20x magnification. 
The excitation wavelength was 509 nm and the emission range was measured from ~500 nm to 





Figure 6-6. SC-1-151 and Ipatasertib treatment in MDA-MB-231 (A) and BT549 (B) TNBC 





Figure 6-7. SC-1-181 potent novel inhibitor of MEK5. Structure of SC-1-181 (A). MDA-MB-
231 cells were treated with various concentrations of SC-1-181 for 1 hour prior to 50ng/mL EGF 





Figure 6-8. Novel MEK5 inhibitor SC-1-181 enhances effect of Akt inhibitor Ipatasertib in 
MDA-MB-231 cells. MDA-MB-231 cells were treated with SC-1-181, Ipatasertib, and CPI203 
alone or in combination for 72 hours under 5% FBS stimulation. Viability was determined with 
the MTT assay. SC-1-181 alone (A). ***P<0.001 and **P<0.01 vs control. SC-1-181 with 
Ipatasertib (B). ***P<0.001 and ****P<0.0001 vs control. SC-1-181 plus Ipatasertib and CPI203 





Thiophenes are another structural class that has been shown to inhibit MEK at the type III 
site (Laing et al. 2012). The compound from Figure 6-9A exhibited a 20 nM potency for pERK 
activity (Laing et al. 2012). 6-9A contains structural features similar to known type III binders of 
MEK. The docking study revealed a key halogen bond of the 4’Iodo to acyl of Val 127 residue. 
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This is also consistent with our previous molecules such as SC-1-151 where the 4’Iodo was 
observed to be a key component of MEK1/2 activity (Chakabarty et al. 2018). Interestingly, the 
same molecule from 6-9A docked with MEK5 homology model revealed that the 4’Iodo was not 
needed for MEK5. Therefore, we developed molecules without the 4’Iodo in hopes of MEK5 
selectivity (Figure 6-10A). Based on the need for dual inhibition we began to explore other 
scaffolds that could have dual activity. Another benefit of the thiophene structural class is that 
they have been shown to inhibit the PI3K/Akt axis (Liu et al. 2011). MG-3-81 (Figure 6-10A) 
showed promising activity vs pERK5 38% inhibition and pAkt 72% inhibition while sparing 
pERK1/2 11% inhibition (Figure 6-10C). The efficacy of MG-3-81 was examined in MDA-MB-
231 cells. MG-3-81 alone did little to affect cell viability (Figure 6-11A). However, as noted 
with previous compounds, adding the cytostatic agent CPI had a significant effect that was 
greater than each drug alone. CPI (77%) MG-3-81 (90%) and Combo (64%) (Figure 6-11B). 
Even though the response in MDA-MB-231 cells was less than ideal, we began testing in PTEN 
mutant TNBCs to see if the compound would be more effective. MG-3-81 was more effective in 
the BT549 cells and reduced viability in a concentration dependent manner 0.1 (23%), 1 (39%), 
and 10 (65%) (Figure 6-12A). Consistent with previous results MG-3-81 combined with CPI 
reduced viability more than either drug alone CPI (52%), MG-3-81 (39%) and combo (66%) 
(Figure 6-12B). Progress continues with the thiophene series as we aim for greater potency. MG-
5-5 is a recent compound in the thiophene series that had an IC50 of 576 nM for ERK5 and 252 






Figure 6-9. Computational analysis of sevenmebered thiophene in MEK1 and MEK5 
docking studies. Compound from (A) was docked with MEK1 (B; PBD 3SLS) and MEK5 





Figure 6-10. Novel thiophene MG-3-81 inhibits MEK5 and Akt in MDA-MB-231 cells. 
MDA-MB-231 cells were treated with MG-3-81 (A) for 1 hour prior to 50ng/mL EGF 
stimulation for 15 minutes. Docking performed in MOE with MEK5 homology model (B). 





Figure 6-11. Novel dual MEK5/Akt inhibitor MG-3-81 combines with BRD4 inhibitor 
CPI203 to induce apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with 
MG-3-81 alone (A) and in combination with CPI203 (B) for 72 hours under 5% FBS stimulation. 
*P<0.05 and **P<0.01 vs control. #P<0.05 vs drugs alone.  
 
 
Figure 6-12. Novel Dual inhibitor MG-3-81 decreases viability in PTEN mutant BT549 
cells. BT549 cells were treated with MG-3-81 alone (A) or in combination with CPI203 (B) for 
72 hours under 5% FBS stimulation (A). **P<0.01 and ***P<0.001 vs control. *P<0.05 vs both 
drugs alone. BT549 cells cell were treated with MG-3-81 for 1 hour prior to 50ng/mL EGF 






Figure 6-13. Novel thiophene MG-5-5 inhibits MEK5 and Akt in BT549 cells. BT549 cells 
were treated with MG-5-5 (A) for 1 hour prior to 50ng/mL EGF stimulation for 15 minutes. 
pERK5 and pS6 activity determined by western blot (B). IC50 values for pERK5 (C) and pS6 
(D).  
 
6.3.3. Other Applications of Novel inhibitors in U87 Glioblastoma cells 
 
Glioblastoma is a brain malignancy that currently has no targeted therapy. Frontiers for 
targeted therapy in GBM are similar to TNBC in that genetic aberrations in the PI3K/Akt have 
been identified as promising targets. The U87 GBM cell line was selected due to its PTEN and 
treatment resistance status. The U87 cell line was also used because we observed cross-activation 
between Akt and MEK5/ERK5 in preliminary studies (Figure 1-14).  
U87 glioblastoma (GBM) cells (PTEN mutant) were treated with our most promising 
leads for MEK5 and MEK5/Akt inhibition: SC-1-181 and MG-3-81, respectively. SC-1-181 was 
added alone or in combination to TMZ, the standard of care for GBM (Lee 2016). U87 cells are 
resistant to TMZ and, SC-1-181 was unable to potentiate the conventional therapy (Figure 6-
14A). However, SC-1-181 did significantly decrease colony formation at 10  𝜇M (55% of 
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control) (Figure 6-14B). Additionally, SC-1-181 had an effect on CD133 expression, which is a 
stem cell marker for GBM (Figure 6-14C). The dual inhibitor, MG-3-81, reduced viability in 
U87 cell by 75% at 10  𝜇M (Figure 6-15). Overall these findings suggest that the ERK5 plays a 




Figure 6-14. Novel MEK5 inhibitor SC-1-181 inhibits colony formation in PTEN mutant 
U87 glioblastoma cells. U87 cells were treated with SC-1-181 alone or in combination with 
TMZ for 96 hours under 5% FBS stimulation (A). Cell viability determined using the MTT 
assay. Colony formation was measured after SC-1-181 treatment for 6 days using kit (B). 







Figure 6-15. Novel Dual inhibitor MG-3-81 reduces viability in U87 cells. U87 cells were 
treated with MG-3-81 for 96 hours under 5% FBS stimulation. Cell viability was determine by 
the MTT assay. ****P<0.0001 vs DMSO control. (Seraina Schottland, Unpublished work). 
 
6.4 Discussion  
 
 The inhibitors used to study MEK5/ERK5 are limited and primarily ATP-competitive. In 
this study, we demonstrated the utility of type III inhibitors as a means to achieve selective 
MEK5 inhibition. In particular, SC-1-181 was potent and selective for MEK5 over MEK1/2 
(Figure 6-7). SC-1-181 also recapitulated the functional results from TNBC cells in chapter 4 
(Figure 6-8C). SC-1-181 also exhibited promising activity against stem cells in GBM by 
reducing CD133 expression and colony formation (Figure 6-14). CD133+ U87 cells are crucial 
for tumor formation (Lin B et al. 2017). SC-1-181 decreased CD44+ breast cancer stem cells in a 
TNBC cell line via Jagged1/NOTCH1/MEK5 axis (Ucar et al. 2018). Further studies are needed 
to determine SC-1-181’s effect on U87 stem cells; preferably a cytometry sorting method that 
can identify tagged stem cell populations. Despite the success of SC-1-181 improvements are 
needed to further the current results. Lack of biochemical assays and MEK5 crystal structure are 
limitations to these studies.  
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 The dual MEK5/Akt inhibitor MG-3-81 showed promising activity against ERK5 and 
Akt in MDA-MB-231 and BT-549 TNBC cells. In particular, MG-3-81 alone decreased viability 
in a concentration dependent manner in the PTEN mutant BT-549 cells (Figure 6-12A). 
Additionally, MG-3-81 enhanced the effects of CPI-203 (BRD4 inhibitor) in BT-549 cells 
(Figure 6-12B). These results were similar to what was observed in chapter 5. MG-3-81 also 
decreased viability by 75% in the PTEN mutant U87 glioblastoma cells (Figure 6-15). In Chapter 
5 we observed ERK5 inhibition in the presence of the Akt inhibitor Ipatasertib. Similar signaling 
was observed in neuroblastoma cells where Akt knock out cells had decreased levels of pMEK5 
and pERK5. Furthermore, MEKK3 (upstream of MEK5) was shown to be phosphorylated by 
Akt (Umapathy et al.2014). Interestingly, we observed similar signaling with Ipatasertib in U87 
cells where ERK5 was inhibited. Therefore, we must consider the possibility that our dual 
inhibitors may be inhibiting ERK5 indirectly. Further studies are required to elucidate the role of 
each kinase in the dual inhibitory studies.  
 Additional studies are also needed with the type III inhibitors in mutant models of Akt 
because mutations to the allosteric site can limit their utility. For example, MK2206, an allosteric 
inhibitor of Akt, works well on Akt1 wild type enzyme but does not perform as well on E17K 
mutant Akt forms. The E17K mutation is an activating mutation that occurs in the pleckstrin 
homology (PH) domain of Akt. In particular, AKT1-E17K has been reported in a variety of 
cancers (including breast) and is considered an activating mutation (Brugge et al. 2007). In E17K 
mutant bladder cells MK2206 was unable to inhibit Akt signaling and downstream targets such 
as pS6. On the other hand Ipatasertib, an ATP site binder, (GDC-0068) remained effective even 
in the mutant cell line (Cheng et al. 2015). Therefore we will explore ATP competitive scaffolds 
for selective MEK5 and dual MEK5/Akt inhibition in future studies.  
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Approximately 70% of invasive ductal carcinomas (IDC) are considered estrogen 
receptor alpha (ER) and/or progesterone receptor (PR) positive, and their growth is driven by 
estrogen (Johnston et al. 2003). Initially, ER+ cancers are responsive estrogen receptor 
antagonists such as tamoxifen or aromatase inhibitors (AI) such as letrozole. However, over the 
course of treatment (often 5 years or longer) patients frequently develop resistance (Creighton et 
al. 2009). Tamoxifen and AI treated patients progress over time due to de-novo or acquired 
resistant mechanisms (Clarke et al. 2001, Bachelot et al. 2012). Acquired Tamoxifen resistance 
occurs through several mechanisms: Loss of ER expression, mutations in ligand binding domain, 
alterations to co-activators and co-repressors, aberrant cellular kinase signaling, metabolic 
reprogramming, and stem cell dynamics  (Ring and Dowsett 2004, Chang 2012). ER expression 
is suppressed through epigenetic modifications such as hypermethylation of histone 
deacetylation in vitro (Sharma et al. 2005, Zhou et al. 2007). Mutations in the ligand binding 
domain are another aspect of lost ER function. Mutations to ER are more frequent in vitro and 
have limited prognostic utility clinically (Anderson et al. 1997). Tamoxifen is a selective 
estrogen receptor modulator (SERM) meaning it acts as an agonist in some tissues (uterus) and 
as an antagonist in others (breast). The context of tamoxifen activity is highly dependent on the 
expression levels of co-activator and co-repressors in a tissue (Webb et al. 1998). Therefore, an 
imbalance between co-activator/co-repressor may lead to a shift in Tamoxifen’s activity, thus 
conferring resistance. The PI3K and MAPK pathways have been shown to contribute to 
resistance by phosphorylating ER at Ser 118 (ERK1/2) and Ser 167 (Akt) (Creighton et al. 
2008). This induces ligand independent activation of ER that leads to expression of ER related 
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genes. Additionally, the PI3K and MAPK pathways contribute to resistance by enhancing 
survival and promoting proliferation on E2 ligand independent mechanisms.  
Several clinical trials are under way to address the challenge of tamoxifen resistance. Pre-
clinical combinations of CDK4/6 inhibitor, Palbociclib, plus tamoxifen were synergistic in vitro 
(Finn et al. 2009). Palbociclib is currently in a phase II trial combined with tamoxifen with the 
aim of becoming a first line therapy (NCT02668666). Pan PI3K inhibitor Alplisib and PI3K 
(𝛽  sparing) inhibitor Taselisib are currently under investigation in Phase I tirals as an adjuvant to 
tamoxifen therapy (NCT02058381 and NCT02285179). The MAPK inhibitor LY2228820 was 
also investigated in combination with tamoxifen; however the trial was terminated due to low 
enrollment (Campbell et al. 2013, NCT02322853). New evidence suggests that MEK5/ERK5, a 
member of the MAPK family, is a key component in the proliferation and survival of therapy 
resistant cancers (Drew et al. 2012, Hoang et al. 2017). MEK5/ERK5 has been shown to promote 
ER alpha driven transcription in ER+ breast cancers and actin reorganization and metastasis in 
ER- breast cancers (Erdogan et al. 2014). Furthermore, MEK5/ERK5 promotes hormone 
independent tumorigenesis in breast cancer (Antoon et al. 2013). 
Our initial results indicate that combinations of PI3k/Akt and MEK5/ERK5 blockade are 
promising because they inhibit both the pro-proliferative and pro-metastatic functions in MCF-7 
cells (ER+) (Chapter 3). We propose each pathway contributes to the resistant disease state: 
PI3k/Akt/mTOR (proliferation) and MEK5/ERK5 (survival). Therefore, we hypothesize 
acquired tamoxifen resistant MCF-7 cells will remain sensitive to the dual inhibition of the 
PI3K/Akt and MEK5/ERK5 pathways. The long-term goal of our study is to elucidate the roles 
of PI3k/Akt/mTOR and MEK5/ERK5 in endocrine resistant breast cancer and determine the 
efficacy of a dual inhibition strategy. 
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Hypothesis 7.2  
 
The combination of Akt and ERK5 inhibition will remain effective in an acquired  
 




7.3.1 Establishment of MCF-7 tamoxifen resistant cell line.  
 
Cells were treated for 6 months with 100nM 4OH tamoxifen in charcoal stripped FBS 
and phenol red free medium. Phenol red free medium was used because phenol red has been 
shown to be estrogenic (Rabenoelina et al. 2002). After 6 months the WT and TamR cell lines 
were functionally tested for 4-OH Tamoxifen sensitivity (Figure 7-1A). The WT cell line 
remained sensitive with an IC50 of 455nM while the TamR cell line exhibited a 12 fold higher 
IC50 of 5.46 𝜇M (Figure 6-1A). Additionally, MCF-7 cells treated with 100nM of 4OH 
Tamoxifen had a 2% proliferative fraction (Ki67/Hoechst) whereas, TamR cells under the same 
conditions 65% (Ki67/Hoechst) of cells were actively proliferating (Figure 7-1C). The latter 
suggests the cells were still entering into the cell cycle despite 4OH Tamoxifen being present. 
Lastly, the morphology of the TamR cells also corresponded to the resistant phenotype: TamR 
cells undergo EMT (Figure 7-1C) (Yuan et al. 2015). Next, we performed saturation binding on 
MCF-7 WT and TamR cells using [3H]Estradiol to determine if the affinity for the estrogen 
receptor has changed in the resistant model. Both cell lines exhibited similar affinities: 2.2 nM 
for MCF-7 and 1.1nM for TamR. Also, the Bmax was apparently larger in TamR vs WT 21.4 vs 
4.8, respectively. However, due to the high variability of Bmax in these experiments the values 






Figure 7-1. Generation of 4-OH Tamoxifen resistant MCF-7 cell line. The ER+ MCF-7 cell 
line was treated with 100nM 4OH Tamoxifen for 6 months under 5% Charcoal stripped FBS. 
Cell viability was determined by the MTT assay (A). Proliferation was determined by staining 








Figure 7-2. Both MCF-7 WT and TamR cell lines had similar affinity for [3H]Estradiol 
(E2). MCF-7 WT (A) and TamR (B) were treated with increasing concentrations of 
[3H]Estradiol and saturation binding curves were obtained. Experiment and Analysis carried out 
with the assistance of Dr. Witt-Enderby and students from methods class (GPSC 572). n=4 for 
WT and n=5 for TAMR. Composite saturation binding curves shown.  
 
 
7.3.2 Ipat+XMD decreased viability and ER-ERE complex formation  
 
Once we had established the TamR cell line, we moved to test our hypothesis of 
combination therapy in TamR cells. Based on our initial success with the Akt inhibitor, 
Ipatasertib, we decided to continue using it through out the TamR studies. Ipatasertib alone 
maintained similar potency in both the WT and TamR cell lines with IC50 values of  
6.1 and 8.1 uM, respectively (Figure 7-3A). The ERK5 inhibtor, XMD8-92, was less effective in 
the TamR cell line with an IC50 of 10.1 uM vs 4.0 uM in the WT cells (Figure 6-3B). Next, we 
investigated 1,3 uM of Ipat:XMD in both MCF-7 WT and TamR cells. XMD8-92 alone and in 
combination significantly decreased Hoechst and Ki67 positive cells vs control (Figure 7-4). 
However, only the combination decreased the Hoechst/Ki67 ratio with respect to control. In 
TamR cells, Ipatasetib, XMD8-92 and the combination all significantly decreased Hoechst 
positive cells (Figure 7-4B). Interestingly, the morphology of the WT cells appeared to be 
mesenchymal in cells treated with XMD8-92 (Figure 7-4B). This is consistent with previous 
work that showed BRD4 inhibition induced EMT morphology (Yuan et al. 2015).  
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Next, we examined the binding of ER∝ to ERE in the presence of Estradiol (E2) with an 
ELISA. In the MCF-7 WT cell line, 4-OH tamoxifen worked as expected by decreasing the ER-
ERE complexes in the presence of 10 nM E2 (Figure 7-6A). 4-OH Tamoxifen did not 
significantly reduce the ER-ERE complexes in the TamR cell line in the presence of 10 nM E2 
(Figure 7-6C). Also, the basal level of ER-ERE complexes was elevated in the TamR cells 
(Figure 7-6C). In the experimental groups, XMD8-92 alone or in combination with Ipatasertib 
significantly decreased ER-ERE complexes under 10 nM E2 stimulation in the MCF-7 WT cells 
(Figure 7-6B). BRD4 has been shown to influence ER related gene expression in MCF-7 cells 
(Figure 7-5, Nagarajan et al. 2014). Therefore we used to BRD4 inhibitor CPI-203 to determine 
its effects on ER-ERE complex formation in our model. CPI-203 significantly reduced ER-ERE 
complex formation under 10 nM E2 stimulation in the MCF-7 WT cells (Figure 6-6B). 
Interestingly, XMD8-92 alone or in combination with Ipatasertib decreased ER-ERE complex 





Figure 7-3. MCF-7 and TamR sensitivities to Ipatasertib and XMD8-92.  MCF-7 Wt and 
TamR cells were treated with increasing concentrations of Ipatasertib (A) and XMD8-92 (B). 
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Cell viability determined using the MTT assay. IC50 values deterimed using mirosoft excel. 




Figure 7-4. Ipat+XMD combination decreased proliferation in both MCF-7 Wt and TamR 
cell lines. Cells were treated with 1  𝜇M Ipat and 3  𝜇M XMD alone ore in combination for 72 
hours. Proliferation was determined by staining cells with Ki67 and analysis via 





Figure 7-5. BRD4 role in ER gene expression. Adapted from: Nagarajan et al. 2014. 





Figure 7-6. XMD and CPI decreases ERE-ER binding complexes in MCF-7 WT cells. 
MCF-7 WT (A and B) and TamR (C and D) cells were treated with compounds prior to lysis and 
nuclear extraction. Nuclear extracts were analyzed for active Era complexes with an ERE-ELISA 











7.3.3 XMD8-92 combined with Taselisib decreased viability in MCF-7 and TamR cells 
  
Although an IC50 with Ipatasertib was obtained (Figure 7-3A), a full concentration 
response with IC75 is needed to determine synergy. Therefore, we investigated XMD8-92 in 
combination with Taselisib, a clinically relevant PI3Ka inhibitor. Taselisib decreased viability in 
MCF-7 WT and TamR cells with IC50s of 734 nM and 1.05 uM, respectively (Figure 7-7A and 
C). 1:1 combinations with XMD8-92 decreased viability in both MCF-7 and TamR cell lines 
(Figure 7-7 B and D). In particular, 100 nM each in the MCF-7 and 300 nM each in the TamR 
cells were synergistic combinations with CIs of 0.16 and 0.32, respectively. 
 
Figure 7-7. XMD8-92 synergistically combines with PI3Ka inhibitor Taselisib in MCF-7 
and TamR cells. MCF-7 (top) and TamR (bottom) cells were treated with Taselisib alone (A 
and C) or in combination with XMD8-92 (B and D). Cell viability determined using the MTT 




7.4 Discussion  
 
 We successfully established an acquired tamoxifen resistant model based on viability, 
proliferation, ligand binding, and ER-ERE complex formation. First, the viability of TamR cells 
was 12 fold different than the WT cell line (Figure 7-1A). Additionally, TamR cells remained 
proliferative even in the presence of 4-OH Tamoxifen (Figure 6-1C). Binding of estradiol (E2) 
was similar in both WT and TamR cell lines with Kds of 2.2 nM and 1.1 nM, respectively 
(Figure 7-2). These results were similar to literature values of E2 binding to ER in MCF-7 cells: 
1.8 nM Kd (Brooks et al. 1973). 4-OH Tamoxifen was able to partially abolish the effects of E2 
by reducing ER-ERE complexes in MCF-7 Cells (Figure 7-6A). Again, These results were 
similar to Kling et al. 1998 who showed that ER-Tam complexes had a lower affinity for EREs 
than ER-E2 complexes.  In the TamR cells, 4OH-Tamoxifen was unable to abolish the effects of 
E2 stimulation (Figure 7-6C).  
 Both Ipatasertib and XMD8-92 were able to achieve IC50s in MCF-7 and TamR  
cells (Figure 7-3). However, Ipatasertib was unable to reduce viability past 50% and  
therefore limited synergy interpretations for these cell lines. We utilized 1,3 uM combinations of 
Ipat:XMD in MCF-7 and WT cell lines. The combination significantly decreased Ki67/Hoechst 
ratio (Figure 7-4A and B). The combination also induced a morphological changes in the MCF-7 
WT cell line. One concern was that this phenotype was more invasive however our results from 
chapter 3 demonstrated that LY+XMD MCF-7 cells migrated less than the control. However, 
additional studies are needed with a Boyden chamber invasion assay to confirm that the cells are 
inert. Another feature of the combination was inhibiting ER-ERE complex formation (Figure 7-6 
B and D). In the WT cell line XMD8-92 and CPI-203 (both have BRD4 inhibition properties) 
significantly decreased ER-ERE complexes under E2 stimulation (Figure 7-6B). In the TamR 
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cell line XMD8-92 decreased ER-ERE complexes but only when 4-OH Tamoxifen was present 
(Figure 6-6D). Perhaps this was due to the altered conformation of helix 12 of ER with 4OH 
tamoxifen binding long term (Shiau et al. 1998). Additional studies are needed to determine if 
the effects of XMD8-92 on ER-ERE complex formation affect the expression of ER related 
genes. Additionally, the acquired resistant model has a few caveats such that passaging the cells 
over a long period of time creates a large amount of genetic drift and sequencing would, 
therefore, be needed to determine the extent of the drift and if the kinase pathways we are 
studying are altered. However, it must be said that the PI3K pathway would likely not be altered 
since mutations in the pathway are generally mutually exclusive.  
Lastly, the results from his study have implications for other forms of acquired resistance. 
Our results in chapter 3 indicate that the luminal B (HER2+), triple positive, BT474 cell line was 
sensitive to dual PI3K/ERK5 inhibition. More specifically, the combination significantly reduced 
both viability and migration. Perhaps the combination would also be effective in a Trastuzumab 
(a HER2 antagonist) resistant BT474 model. Additional studies are needed to elucidate the role 



















Chapter 8 Conclusions and Future Directions  
 
 Targeting PI3K/Akt and MEK5/ERK5 was effective across a diverse panel of cell lines. 
The mechanism of synergy or potentiation was not the same for each condition. However, the 
decrease in viability was universal. For example, the Basal B TNBCs MDA-MB-231 and BT-
549 appeared to undergo apoptosis via cleaved caspase-3 activation (Chapters 4 and 5). 
Conversely, Basal A TNBC, MDA-MB-468, did not undergo apoptosis perhaps due to its 
expression of cMET and EGFR. In the tamoxifen resistant cell line the Ipatasertib plus XMD8-
92 worked unexpectedly by inhibiting ER-ERE complex formation. Lastly, novel MEK5 and 
MEK5/Akt inhibitors were able to recapitulate the functional results from chapters 4 and 5. 
Results from these studies are a promising start for targeted TNBC and tamoxifen resistant 
therapy. However, several questions remain and will shape the direction of future experiments.  
 Animal models are needed to examine the potential therapeutic benefit and collateral 
toxicity of these cellular based studies. Using clinical compounds with known PK/PD will 
expedite future animal studies. Additionally, using patient derived xenografts (PDXs) will also 
accelerate the translational potential of these studies. Our collaborators at Tulane and LSU have 
access to TNBC patient samples pretreated with chemotherapy. These samples are converted to 
PDX models, which are a realistic representation of TNBC. However, a limitation of these 
studies is that the PDXs require an immune deficient mouse model. Therefore there is a need to 
investigate in immune competent mouse models as well. Additionally, Ipatasertib has recently 
been shown to enhance the effects of Immunotherapy in TNBC patients. Roche announced the 
results of the phase 1b trial of Ipatasertib and atezolizumab (PD-L1 inhibitor) plus paclitaxel for 
locally advanced TNBC. The trial showed promise with a 73% response rate with patients 
receiving Ipatasertib plus atezolizumab (NCT03800836). Also, the fact that ERK5 inhibition and 
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our novel MEK5 inhibitor did not affect immune response underscore the potential of dual 
PI3K/Akt and MEK5/ERK5 inhibition. 
 Although many of the cell lines in this study share similar “driver” mutations, there were 
marked divergences in cellular signaling. To address this future studies characterizing the 
upstream kinases of MEK5: MEKK2 and MEKK3 should be conducted. Also, the role of 
ERK1/2 in EMT needs to be further evaluated. Lastly, in these studies, drugs were 
simultaneously applied for treatment. Future studies should examine the temporal component of 
the combination strategy.  
 In summary, the results of this dissertation indicate, for the first time, the therapeutic 
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